var title_f14_60_15296="Eschar in scrub typhus";
var content_f14_60_15296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eschar in scrub typhus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A localized necrotic skin lesion (eschar) at the site of an infecting chigger bite in a patient with scrub typhus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel J Sexton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15296=[""].join("\n");
var outline_f14_60_15296=null;
var title_f14_60_15297="Patient information: Tinea nigra (The Basics)";
var content_f14_60_15297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/46/42722\">",
"         Patient information: Melanoma skin cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/47/24305\">",
"         Patient information: Tinea versicolor (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tinea nigra (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tinea-nigra-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29546761\">",
"      <span class=\"h1\">",
"       What is tinea nigra?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tinea nigra is a skin infection that causes tan, brown, or black patches on the skin. It is caused by a fungus.",
"     </p>",
"     <p>",
"      Tinea nigra is most common in areas where the weather is hot and humid. People whose hands or feet sweat a lot are more likely to get it. This is because the fungus that causes tinea nigra grows best in warm, wet places. &nbsp;",
"     </p>",
"     <p>",
"      Tinea nigra is not &ldquo;contagious.&rdquo; That means it does not usually spread from one person to another.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29546776\">",
"      <span class=\"h1\">",
"       What are the symptoms of tinea nigra?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is tan, brown, or black patches on the skin. These are most common on certain body parts, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Palm or back of the hand &ndash; This usually happens in just 1 hand.",
"       </li>",
"       <li>",
"        Bottom of the foot",
"       </li>",
"       <li>",
"        Arms or legs",
"       </li>",
"       <li>",
"        Neck",
"       </li>",
"       <li>",
"        Chest, back, or belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The brown or black patches might look darker around the edges. They do not usually itch, hurt, or cause any other symptoms. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29546791\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tinea nigra is not dangerous. But a type of skin cancer called &ldquo;melanoma&rdquo; can also cause brown or black spots on the skin. If you get a new brown or black spot on your skin, ask your doctor or nurse to check it. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29546806\">",
"      <span class=\"h1\">",
"       Is there a test for tinea nigra?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. After learning about your symptoms and doing an exam, your doctor or nurse will probably scrape one of the brown or black patches. Then he or she will look at the scrapings under a microscope. This test does not usually hurt.",
"     </p>",
"     <p>",
"      If you have tinea nigra, the doctor or nurse will see the fungus that causes it in the scrapings from your skin. He or she might also use a special light to look at your skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29546821\">",
"      <span class=\"h1\">",
"       How is tinea nigra treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor or nurse can prescribe a cream or ointment to put on your skin. This usually makes tinea nigra go away.",
"     </p>",
"     <p>",
"      If the cream or ointment does not work, the doctor or nurse can prescribe medicine you take by mouth. This medicine kills the fungus that causes tinea nigra.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29546836\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/47/24305?source=see_link\">",
"       Patient information: Tinea versicolor (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=see_link\">",
"       Patient information: Melanoma skin cancer (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/60/15297?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83426 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15297=[""].join("\n");
var outline_f14_60_15297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29546761\">",
"      What is tinea nigra?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29546776\">",
"      What are the symptoms of tinea nigra?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29546791\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29546806\">",
"      Is there a test for tinea nigra?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29546821\">",
"      How is tinea nigra treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29546836\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=related_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/47/24305?source=related_link\">",
"      Patient information: Tinea versicolor (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15298="Patient information: Ehlers-Danlos syndrome (The Basics)";
var content_f14_60_15298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86966\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/52/33614\">",
"         Wrist hypermobility",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/4/21571\">",
"         Patient information: Mitral valve prolapse (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ehlers-Danlos syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H61435904\">",
"      <span class=\"h1\">",
"       What is Ehlers-Danlos syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ehlers-Danlos syndrome is the name for a group of conditions that have similar symptoms. Ehlers-Danlos syndrome involves the body&rsquo;s connective tissues, which are the tissues that make up and support the skin, bones, blood vessels, and other organs. A part of the connective tissue, called collagen, is abnormal in people with Ehlers-Danlos syndrome.",
"     </p>",
"     <p>",
"      Ehlers-Danlos syndrome is a life-long condition that people are born with. It is caused by an abnormal gene. In most cases, people get Ehlers-Danlos syndrome when they get the abnormal gene from either their mother or father.",
"     </p>",
"     <p>",
"      There are different types of Ehlers-Danlos syndrome. Each type has slightly different symptoms, but all of them affect the joints and skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61435919\">",
"      <span class=\"h1\">",
"       What are the symptoms of Ehlers-Danlos syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms of Ehlers-Danlos syndrome include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stretchy skin &ndash; When pulled, the skin stretches more than normal. The medical term for this is &ldquo;hyperelasticity.&rdquo;",
"       </li>",
"       <li>",
"        Easy bruising of the skin",
"       </li>",
"       <li>",
"        Thin skin that can get cut easily &ndash; Cuts can take longer to heal. When they heal, they often leave abnormal-looking scars.",
"       </li>",
"       <li>",
"        Joints that are too loose and stretch more than normal &ndash; The medical term for this is &ldquo;hypermobility&rdquo; (",
"        <a class=\"graphic graphic_picture graphicRef86921 \" href=\"UTD.htm?32/52/33614\">",
"         picture 1",
"        </a>",
"        ). Loose joints can lead to problems, such as muscle and bone pain or joint damage.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some types of Ehlers-Danlos syndrome can lead to serious problems. For example, some people with Ehlers-Danlos syndrome have a heart valve problem called mitral valve prolapse. The most serious problem people can get is a sudden tear in a blood vessel. When this happens, it is most often in the brain, neck, or chest. This can cause bleeding in the body and be life threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61435957\">",
"      <span class=\"h1\">",
"       Is there a test for Ehlers-Danlos syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can order a blood test to check for the gene that causes the condition.",
"     </p>",
"     <p>",
"      Your doctor might also do a test called a skin biopsy. For this test, he or she will take a tiny piece of your skin. Then another doctor will do lab tests on the sample.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61435972\">",
"      <span class=\"h1\">",
"       How is Ehlers-Danlos syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for Ehlers-Danlos syndrome. But your doctor can treat problems you have from the condition, such as bone or joint pain. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Physical therapy &ndash; You can work with a physical therapist (exercise expert) to learn exercises to strengthen your muscles and joints.",
"       </li>",
"       <li>",
"        Braces that you wear on your knee to help support it",
"       </li>",
"       <li>",
"        Pain-relieving medicines &ndash; Your doctor might recommend that you take a nonsteroidal anti-inflammatory drug, or &ldquo;NSAID&rdquo; for short. Examples of NSAIDs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (brand name: Aleve). If NSAIDs don&rsquo;t ease your pain enough, your doctor can prescribe stronger pain medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61435987\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can do things to help take care of your joints and skin. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid contact sports or other activities that can easily cause injuries.",
"       </li>",
"       <li>",
"        Get exercise, but make sure to stop when your joints or muscles start to hurt.",
"       </li>",
"       <li>",
"        Avoid sitting cross-legged or with your knees tucked under you.",
"       </li>",
"       <li>",
"        Use mild soaps and sunscreens that don&rsquo;t bother your skin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61436002\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse before you start trying. If you or your partner has Ehlers-Danlos syndrome, your children have a chance of getting it, too. You will probably want to meet with a genetic counselor. This is a person who specializes in genetic problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61436017\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on which type of Ehlers-Danlos syndrome you have. If you have a very mild type, you will have stretchy skin and loose joints only. But if you have the most serious type, there is a chance you will have life-threatening internal bleeding.",
"     </p>",
"     <p>",
"      To get more information about what to expect, you might want to talk with a specialist in medical genetics who has experience with Ehlers-Danlos syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H61436032\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       Patient information: Mitral valve prolapse (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/60/15298?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86966 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.179.173.170-A48E13D4B1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15298=[""].join("\n");
var outline_f14_60_15298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61435904\">",
"      What is Ehlers-Danlos syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61435919\">",
"      What are the symptoms of Ehlers-Danlos syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61435957\">",
"      Is there a test for Ehlers-Danlos syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61435972\">",
"      How is Ehlers-Danlos syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61435987\">",
"      Is there anything I can do on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61436002\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61436017\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61436032\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/52/33614\">",
"      Wrist hypermobility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15299="Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy";
var content_f14_60_15299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15299/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15299/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15299/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15299/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15299/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15299/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/60/15299/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 38-year-old woman, whom you have treated for type 1 diabetes for many years, comes in for an urgent office visit because her blood glucose values have risen markedly in the last few days. One week ago, she was started by her allergist on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60 mg every morning for asthma not responsive to conservative therapy including an inhaled glucocorticoid. She responded well with a marked reduction in symptoms, improvement in the peak expiratory flow rate, and improved exercise tolerance.",
"   </p>",
"   <p>",
"    The patient has had diabetes since age 17, complicated by proliferative retinopathy previously treated with laser therapy, nephropathy with microalbuminuria and hypertension, and distal sensory neuropathy. She is treated with NPH insulin 14 units and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    8 units before breakfast, regular insulin 10 units before supper and NPH insulin 6 units at bedtime. Since the development of proliferative retinopathy with impaired vision in the left eye four years ago, she has been very attentive to management of her diabetes. She checks her blood glucose four times a day and brings a printout of her glucometer readings to each office visit. Her current 15-day blood glucose average is 181",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    the 30 day average is 142",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The table shows blood glucose values",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    before and after the start of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81444 \" href=\"UTD.htm?6/24/6539\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most recent hemoglobin A1C, obtained three weeks before the start of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , was 6.9 percent.",
"   </p>",
"   <p>",
"    Physical examination reveals an anxious woman who is in no acute distress. Blood pressure is",
"    <span class=\"nowrap\">",
"     145/90",
"    </span>",
"    right arm supine,",
"    <span class=\"nowrap\">",
"     140/95",
"    </span>",
"    right arm upright, heart rate 84 regular, weight 126 pounds, height 5' 1\", body mass index 23.8. The right fundus reveals evidence of previous photocoagulation therapy but no fresh hemorrhages or neovascular changes. The left fundus is similar but also reveals cicatrix formation inferior to the nerve head. The chest examination reveals scattered expiratory wheezes in all fields but no prolongation of expiration. Cardiac examination is within normal limits. The dorsal pedal pulses are absent bilaterally. The right posterior tibial pulse is 2+, the left is absent. Sensation to light touch is absent to the tibial tubercles. Vibratory sensation is absent at the great toes, markedly reduced at the medial malleoli and nearly normal at the tibial tubercles. Knee jerks and ankle jerks are absent bilaterally.",
"   </p>",
"   <p>",
"    The patient's medications, other than insulin, are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    10 mg once a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    81 mg a day, Advair Discus",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"      fluticasone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"      salmeterol",
"     </a>",
"     )",
"    </span>",
"    <span class=\"nowrap\">",
"     250/50,",
"    </span>",
"    one inhalation twice a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    inhaler two puffs every four hours as needed and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    10 mg once a day.",
"   </p>",
"   <p>",
"    How would you manage the patient's diabetes at this time?",
"   </p>",
"   <p>",
"    A1 &ndash; You add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    1.000 mg twice a day with meals to reduce hepatic glucose output. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a1?source=see_link\">",
"     \"Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A2 &ndash; You discuss with the patient and the allergist the expected duration of systemic glucocorticoid therapy before proceeding further. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a2?source=see_link\">",
"     \"Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A3 &ndash; You increase the dose of NPH insulin to 20 units before breakfast and 10 units at bedtime. You add to the current doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    before breakfast and supper an insulin correction factor before meals and at bedtime using a generous correction factor of 20, that is one unit of short-acting (regular) insulin for every 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    elevation of the blood glucose level above a reference point of 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    approximately twice the correction factor one might otherwise use. (Based on the patient's insulin doses before the start of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and using the rule of 1500, the correction factor would otherwise be 39.5). An approach to estimating the dose of short and very short-acting insulins is discussed separately. (See",
"    <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2?source=see_link\">",
"     \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2\"",
"    </a>",
"    .) You anticipate further adjustment of the new insulin regimen as the patient monitors the blood glucose values on it and as the dose of prednisone is tapered. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a3?source=see_link\">",
"     \"Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A3\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A4 &ndash; You admit the patient to the hospital for an intravenous insulin infusion to control the hyperglycemia rapidly and then to adjust the patient's daily insulin regimen. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a4?source=see_link\">",
"     \"Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A4\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4157 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15299=[""].join("\n");
var outline_f14_60_15299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/4157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/4157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/24/6539\" title=\"table 1\">",
"      Prednisone insulin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a1?source=related_link\">",
"      Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a2?source=related_link\">",
"      Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a3?source=related_link\">",
"      Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?14/60/15299-a4?source=related_link\">",
"      Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15300="Naphazoline (ophthalmic): Drug information";
var content_f14_60_15300=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naphazoline (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19188?source=see_link\">",
"    see \"Naphazoline (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/60/27587?source=see_link\">",
"    see \"Naphazoline (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15512118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning on Accidental Ingestion of Imidazoline Derivative Eye Drops and Nasal Sprays",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) has issued a warning that accidental ingestion by children of over-the-counter (OTC) imidazoline derivative eye drops and nasal sprays may result in serious harm. The eye drops and nasal sprays involved in cases of accidental ingestion contain the imidazoline derivatives tetrahydrozoline, oxymetazoline, or naphazoline. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization were reported in children &le;5 years who had ingested even small amounts (eg, 1-2 mL). These products should be stored out of reach of children at all times; parents and caregivers should note that not all products are packaged in child-resistant packaging. If a child accidentally ingests these products, parents and caregivers should contact a poison control center at 1-800-222-1222 and seek emergency medical care immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, please refer to:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9348239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Con&trade;;",
"     </li>",
"     <li>",
"      Clear eyes&reg; for Dry Eyes Plus ACR Relief [OTC];",
"     </li>",
"     <li>",
"      Clear eyes&reg; for Dry Eyes plus Redness Relief [OTC];",
"     </li>",
"     <li>",
"      Clear eyes&reg; Redness Relief [OTC];",
"     </li>",
"     <li>",
"      Clear eyes&reg; Seasonal Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9348240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naphcon Forte&reg;;",
"     </li>",
"     <li>",
"      Vasocon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9348259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       1",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Imidazoline Derivative;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Vasoconstrictor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9348309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Decrease in eye redness (vasoconstrictor):",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     0.1% solution (prescription): 1-2 drops into conjunctival sac every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     0.012% or 0.025% solution (OTC): 1-2 drops into affected eye(s) up to 4 times/day; therapy should not exceed 3 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9348311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9348361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Con&trade;: 0.1% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clear eyes&reg; for Dry Eyes Plus ACR Relief: 0.025% (15 mL) [contains hypromellose, zinc sulfate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clear eyes&reg; for Dry Eyes plus Redness Relief: 0.012% (15 mL) [contains benzalkonium chloride, glycerin, hypromellose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clear eyes&reg; Redness Relief: 0.012% (6 mL, 15 mL, 30 mL) [contains benzalkonium chloride, glycerin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clear eyes&reg; Seasonal Relief: 0.012% (15 mL, 30 mL) [contains benzalkonium chloride, glycerin, zinc sulfate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9348242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9348317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Contact lenses should be removed prior to administering products containing benzalkonium chloride.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9348243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical ocular vasoconstrictor; relief of redness of the eye due to minor irritation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15801079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9348282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Blurred vision, discomfort, intraocular pressure increased, irritation, lacrimation, mydriasis, punctuate keratitis, redness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9348247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naphazoline or any component of the formulation; narrow-angle glaucoma or anatomically narrow angle",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9348250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypertension, heart failure, or  coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection/injury: Use with caution in patients with local infection or injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Avoid concurrent use with MAO inhibitors; may cause hypertensive crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzalkonium chloride: Ophthalmic products may contain benzalkonium chloride which may be absorbed by soft contact lenses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Patients should notify healthcare provider if symptoms last &gt;48 hours (&gt;72 hours if using OTC product) or if condition worsens. Contact prescriber in case of eye pain or if changes in vision occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9348288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9348244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9348245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9348246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clear Eyes Redness Relief Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.012-0.2% (6 mL): $1.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Naphazoline HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 mL): $7.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (VasoClear Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02% (15 mL): $9.73",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Albalon (AE, BH, CH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, NL, OM, QA, SA, SY, TH, YE);",
"     </li>",
"     <li>",
"      Albalon Liquifilm (AU, NZ);",
"     </li>",
"     <li>",
"      Albasol (CO);",
"     </li>",
"     <li>",
"      Alivioftal (CO);",
"     </li>",
"     <li>",
"      All Clear (HK);",
"     </li>",
"     <li>",
"      Claroft (BR);",
"     </li>",
"     <li>",
"      Clear Eyes (NZ);",
"     </li>",
"     <li>",
"      Clearine (IN);",
"     </li>",
"     <li>",
"      Mirasan (AR);",
"     </li>",
"     <li>",
"      Murine Clear Eyes (AU);",
"     </li>",
"     <li>",
"      Naftazolina (IT);",
"     </li>",
"     <li>",
"      Naphcon (AE, BE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Naphcon Forte (AE, AU, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Naphcon-F (CO);",
"     </li>",
"     <li>",
"      Naphtears (CN, PE, PK, PY);",
"     </li>",
"     <li>",
"      Red Off (UY);",
"     </li>",
"     <li>",
"      Sanorin (CZ, EE);",
"     </li>",
"     <li>",
"      Tele-Stulin (DE);",
"     </li>",
"     <li>",
"      Vasoclear-V (PH);",
"     </li>",
"     <li>",
"      Vericlar (GT, HN, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9348297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9856 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15300=[""].join("\n");
var outline_f14_60_15300=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512118\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348259\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348309\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348311\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348361\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348242\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348317\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348243\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15801079\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348282\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348247\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348250\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299742\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348288\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348244\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348245\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348246\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322359\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390234\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348297\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/53/29523?source=related_link\">",
"      Naphazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/52/40772?source=related_link\">",
"      Naphazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/57/10131?source=related_link\">",
"      Naphazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19188?source=related_link\">",
"      Naphazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/60/27587?source=related_link\">",
"      Naphazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15301="Solar lentigines";
var content_f14_60_15301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solar lentigines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous tan macules with irregular borders on the posterior neck and shoulder of an adolescent with a history of several severe sunburns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15301=[""].join("\n");
var outline_f14_60_15301=null;
var title_f14_60_15302="Ultrasound of cranium in osteogenesis imperfecta type 2";
var content_f14_60_15302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Ultrasound of cranium in osteogenesis imperfecta type 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Osteogenesis imperfecta Type 2 with demineralization of the cranial vault.",
"    <br>",
"     (A) Cranial vault appears normally mineralized.",
"     <br>",
"      (B) Mild transducer pressure over the cranial vault results in flattening of the skull.",
"      <br>",
"       (C) Caput membranacae or membranous coverings of the intracranial content occurs when the demineralization is so significant that no appreciable calvarium bone ossification has occurred. Note the absence of a bright wall line representing ossified bone, which should normally encircle the intracranial contents.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15302=[""].join("\n");
var outline_f14_60_15302=null;
var title_f14_60_15303="Serous cystadenoma Light II";
var content_f14_60_15303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pancreatic serous cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light microscopic appearance of a pancreatic serous cystadenoma (H&amp;E stain). Note cuboidal cells lining cystic spaces and amorphous stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael L Steer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15303=[""].join("\n");
var outline_f14_60_15303=null;
var title_f14_60_15304="Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)";
var content_f14_60_15304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15304/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15304/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15304/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/60/15304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular nodal reentrant tachycardia (AVNRT) is one of the more common supraventricular tachycardias (SVTs). Because of its abrupt onset and termination, AVNRT is categorized among the paroxysmal SVTs (PSVTs). It is the most common of the PSVTs, accounting for nearly two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Paroxysmal SVT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter ablation of AVNRT with radiofrequency (RF) energy or cryotherapy is a safe and effective curative treatment of the arrhythmia. For patients with frequent symptomatic recurrences of AVNRT, RF ablation (RFA) is emerging as the preferred treatment strategy. In addition, because of its favorable safety and efficacy profile, RFA is also a reasonable option for the treatment of patients with less frequent episodes of AVNRT, regardless of symptom severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H31#H31\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion will focus upon ablation therapy for AVNRT. However, many patients undergo electrophysiology (EP) study and ablation for evaluation and management of SVT without a specific diagnosis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Patient selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This card will discuss the role of catheter ablation in the management of AVNRT. A detailed discussion of the clinical features of AVNRT and a more general discussion of catheter ablation of cardiac arrhythmias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNDERLYING PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the catheter ablation of AVNRT is based upon the concept of dual AV nodal pathways. These pathways may be distinct anatomic structures, or may be functionally separate (ie, regions that appear anatomically continuous, but have different electrical properties). In the most common forms of AVNRT, the dual pathways have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One pathway conducts rapidly and has a relatively long refractory period. This is called the fast or beta pathway.",
"     </li>",
"     <li>",
"      The second pathway conducts relatively slowly, but has a shorter refractory period. This is called the slow or alpha pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During normal rhythm, the sinus beat enters both the fast and slow pathways. The impulse traveling down the fast pathway reaches the His bundle first, creating a refractory wake that blocks the later-arriving impulse from the slow pathway (",
"    <a class=\"graphic graphic_figure graphicRef79760 \" href=\"UTD.htm?1/35/1598\">",
"     figure 1",
"    </a>",
"    ). This sequence results in a single conducted beat with a normal PR interval. Under certain circumstances, however, these pathways can create a reentrant circuit, producing episodes of tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H7#H7\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Dual AV nodal physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common AVNRT circuit (80 to 90 percent of arrhythmias) involves antegrade conduction down the slow pathway and retrograde conduction up the fast pathway (slow-fast tachycardia). Atypical forms of AVNRT (observed in up to 20 percent of patients) involve either the reverse circuit, with antegrade conduction down the fast pathway and retrograde conduction up a slow pathway (fast-slow tachycardia) or a circuit in which both the antegrade and retrograde limbs are slow pathways (slow-slow tachycardia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11043421\">",
"    <span class=\"h1\">",
"     RADIOFREQUENCY ABLATION VERSUS CRYOABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-based radiofrequency ablation (RFA) has been the preferred means of ablation for AVNRT, given its high short- and long-term success rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As with nearly every invasive procedure, there are potential complications associated with RFA when used to treat AVNRT, most notably the potential for AV block. These complications are discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ablation using cryotherapy has been proposed as an equally efficacious and potentially safer means of treating AVNRT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the potential safety improvements with cryoablation, the most notable appears to be the potential to avoid heart block. Relative to RFA, cryoablation allows for a more gradual temperature change that results in conduction block before permanent necrosis occurs. When AV block occurs inadvertently during cryoablation, termination of cryoenergy delivery is almost always followed by recovery of conduction as the tissue warms. The safety margin for RF energy is significantly lower [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of cryoablation in the treatment of AVNRT has been evaluated in numerous cohorts and randomized trials. In the largest randomized trial of cryoablation versus RFA, the Cryoablation Versus Radiofrequency Energy for the Ablation of Atrioventricular Nodal Reentrant Tachycardia (CYRANO) study, 509 patients were randomized to cryoablation or RFA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/8\">",
"       8",
"      </a>",
"      ]. While there was no significant difference in immediate ablation success (96.8 versus 98.4 percent) or permanent AV block (0 versus 0.4 percent) between the two groups, late recurrence of AVNRT was significantly more frequent in the cryoablation group (9.4 versus 4.4 percent).",
"     </li>",
"     <li>",
"      In a 2012 review that pooled data from nine studies (four randomized trial, five cohorts) comparing cryoablation (900 patients) with RFA (917 patients), the initial procedural success was high (approximately 95 percent) and comparable between both techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/7\">",
"       7",
"      </a>",
"      ]. However, a higher rate of recurrence was seen in patients undergoing cryoablation (11 versus 4 percent with RFA).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While cryoablation appears safe and efficacious in the short term, rates of long-term maintenance of sinus rhythm do not appear as good as those achieved with RFA. As such, RFA should remain the first-line ablation option for most adult patients with AVNRT who require ablation. However, cryoablation has become widely adopted for ablation of AVNRT at many pediatric centers, where the ablation target can be much smaller and the impact of inadvertent heart block is much greater.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMPORTANT ANATOMY AND TARGETING THE SITE OF ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact anatomical distribution of the pathways involved in AVNRT is uncertain, but they are typically localized within a region of the right atrium called Koch's triangle. Koch's triangle is bounded by the tricuspid ring, the tendon of Todoro, and the coronary sinus; the apex of the triangle is near the His bundle at the membranous septum (",
"    <a class=\"graphic graphic_figure graphicRef69647 \" href=\"UTD.htm?12/17/12562\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an approximation, Koch's triangle can be divided into thirds (",
"    <a class=\"graphic graphic_figure graphicRef52196 \" href=\"UTD.htm?25/31/26096\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The anterior third, which contains the AV node and the fast pathways",
"     </li>",
"     <li>",
"      The middle third",
"     </li>",
"     <li>",
"      The posterior third, the usual site of slow pathways",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High resolution mapping indicates that retrograde fast pathway conduction during the common slow-fast form of AVNRT causes the earliest atrial activation at the apex of Koch's triangle in the vicinity of the junction between the AV node and the bundle of His [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/9\">",
"     9",
"    </a>",
"    ]. Retrograde slow pathway conduction during the uncommon fast-slow form of AVNRT activates the atrium earliest in the lower (most frequent) or middle portion of Koch's triangle near the os of the coronary sinus.",
"   </p>",
"   <p>",
"    The most common ablation target is the posterior slow pathway (",
"    <a class=\"graphic graphic_figure graphicRef52196 \" href=\"UTD.htm?25/31/26096\">",
"     figure 3",
"    </a>",
"    ). The anterior fast pathway can also be ablated, but this approach is now largely of historical interest; its use in clinical practice is limited to special circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Posterior approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior approach delivers the RF energy in the middle or posterior septal region near the coronary sinus ostium with the slow pathway as the target (",
"    <a class=\"graphic graphic_figure graphicRef62108 \" href=\"UTD.htm?18/15/18673\">",
"     figure 4",
"    </a>",
"    ). The target site is usually determined by anatomic position",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by the morphology of the electrogram (",
"    <a class=\"graphic graphic_waveform graphicRef77513 graphicRef58652 \" href=\"UTD.htm?16/32/16905\">",
"     waveform 1A-B",
"    </a>",
"    ). The use of intracardiac echocardiography to guide the selection of ablation sites has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most electrophysiologists begin ablation in the posterior third of Koch's triangle. Reasons for targeting the slow pathway and beginning in the posterior section of Koch's triangle include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This segment is furthest from the His bundle and therefore ablation in this area carries the lowest risk of AV block.",
"     </li>",
"     <li>",
"      Ablation of the slow pathway preserves fast pathway function, and therefore a normal PR interval after the ablation.",
"     </li>",
"     <li>",
"      Reliable anatomic and electrophysiologic landmarks facilitate selection of a safe and effective ablation site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typically, the ablation electrode is positioned near the tricuspid valve annulus at the level of the coronary sinus ostium. A good ablation site records a small fractionated or multicomponent atrial potential, generally less than 20 percent of the ventricular electrogram amplitude. If slow pathway conduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inducible AVNRT persist after initial RF lesions, subsequent ablations may be necessary with the electrode withdrawn slightly into the atrium, closer to the ostium of the coronary sinus.",
"   </p>",
"   <p>",
"    Approximately 90 percent of successful slow pathway ablation sites are found between the coronary sinus ostium and the tricuspid valve. Occasionally, ablation lesions must be delivered within the proximal coronary sinus or on the opposite side of the septum at the left posteroseptal region to achieve successful ablation of the slow pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hands of experienced operators, the posterior approach eliminates arrhythmia recurrence in over 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. Evidence of dual pathway physiology can persist in one-third to one-half of cases, but it is not necessary to eliminate all slow pathway conduction to achieve clinical success (ie, elimination of arrhythmia recurrence). If the slow pathway is damaged but not completely abolished, it may be possible to induce single atrial echoes even though the sustained arrhythmia has been eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anterior approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior approach to ablation delivers the RF energy in the anterior third of Koch's triangle, somewhat anterior and proximal to the His Bundle, targeting the fast pathway (",
"    <a class=\"graphic graphic_figure graphicRef62108 \" href=\"UTD.htm?18/15/18673\">",
"     figure 4",
"    </a>",
"    ). Although the success rate rivals the posterior approach, the risk of creating complete AV block with ablations in this area is higher than in the posterior third of Koch's triangle (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Complications'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/1,19-22\">",
"     1,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anterior approach is now limited to unusual circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/23\">",
"     23",
"    </a>",
"    ]. In rare patients, AVNRT may occur in patients who, during normal sinus rhythm, have a markedly prolonged PR interval and absent antegrade fast pathway conduction. In such patients, the posterior approach and slow pathway ablation may result in complete heart block and the need for a permanent pacemaker. Although data are limited, selective ablation of the retrograde fast pathway in this setting can eliminate the AVNRT without further impairment of AV nodal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/24\">",
"     24",
"    </a>",
"    ]. Fast pathway ablation can also be considered in patients who have previously had unsuccessful slow pathway ablation. However, this approach carries an increased risk of AV block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anatomic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AVNRT appear to have larger coronary sinus ostia relative to patients with other forms of SVT, and an exceptionally large coronary sinus ostium distorts the usual fluoroscopic anatomy of Koch's triangle. In addition, in approximately 5 to 10 percent of patients, Koch's triangle assumes a horizontal orientation, as has been demonstrated by electroanatomical mapping studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/25\">",
"     25",
"    </a>",
"    ]. Failure to recognize these anatomic variants may be associated with an increased risk of AV block if the operator relies on the typical fluoroscopic appearance alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/26\">",
"     26",
"    </a>",
"    ]. Careful definition of the location and relationship between the His bundle and the coronary sinus ostium, either with multiple fluoroscopic views or electroanatomic mapping, prior to RF application, is important to avoid this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Atypical forms of AVNRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with atypical forms of AVNRT, the most common approach is to target the site of earliest retrograde atrial activation identified by mapping of the retrograde pathway during tachycardia. For the fast-slow form of AVNRT, these typically cluster in the posteroseptal right atrium outside the coronary sinus ostium. In the slow-slow form of AVNRT, the earliest retrograde activation is most often seen within the proximal coronary sinus, particularly the superior portion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence rates after ablation of atypical AVNRT is higher than in typical forms and can exceed 10 percent. It has been suggested that empiric slow pathway ablation targeting the \"usual\" anatomic site just anterior to the roof of the coronary sinus ostium may be equally or more effective in eliminating atypical forms of AVNRT and in preventing long term recurrence. This latter observation suggests that all forms of AVNRT share a common anatomic substrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general complications associated with catheter ablation procedures are discussed in detail separately. Several additional considerations are important in the ablation of AVNRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most significant potential complication of RFA for AVNRT is AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/15\">",
"     15",
"    </a>",
"    ]. Complete AV block is less common (about 1 percent, range 0 to 3 percent) with the posterior than the anterior approach. Most cases of AV block occur after ablation to the middle third of Koch's triangle (",
"    <a class=\"graphic graphic_figure graphicRef69647 \" href=\"UTD.htm?12/17/12562\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    AV block may not be immediately observed, but may progress following the procedure. However, this is extremely rare in patients who did not have transient AV block during the ablation. The occurrence of retrograde AV block of junctional beats during RF energy application may signal impending injury to the compact AV node, and energy application should be terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of cryothermal ablation of the slow pathway is an approach that may reduce the potential for AV block; the ability to test prospective ablation sites before permanent destruction can prevent this inadvertent complication [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Risk factors for AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single factor or patient profile can prospectively identify those individuals who will develop AV block. However, several factors may predict an increased risk of this complication. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; In a series of 271 patients who underwent RFA for AVNRT, the incidence was 0, 2, and 8 percent in patients under 45 years of age, 45 to 65 years of age, and over age 65, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The development of a fast junctional tachycardia (cycle length &lt;350 ms) during the ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Baseline PR prolongation &mdash; Some series have suggested an increased risk of AV block in patients with baseline PR prolongation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/32\">",
"       32",
"      </a>",
"      ], while others have shown that RF ablation is safe in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A relatively long refractory period in the fast pathway had been suggested as a potential risk factor for AV block. However, in a series of 18 such patients who underwent RFA, there were no cases of AV block at a mean follow-up of 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less severe complications that can occur following AVNRT ablation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpitations occur in 20 to 30 percent of patients following ablation of AVNRT. These are generally transient, and usually not due to recurrent AVNRT. Most are due to premature atrial or ventricular contractions, which subside spontaneously and require no treatment other than reassurance.",
"     </li>",
"     <li>",
"      An inappropriate sinus tachycardia may be present in some patients after the ablation of AVNRT or other SVTs, suggesting disruption of the parasympathetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sympathetic inputs into the sinus and AV nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/36-38\">",
"       36-38",
"      </a>",
"      ], although the role of autonomic disruption is not certain [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/39\">",
"       39",
"      </a>",
"      ]. The sinus tachycardia most commonly subsides within six months of ablation. When highly symptomatic, it can be treated temporarily with beta blockers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ABLATION VERSUS MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the management of AVNRT, RFA compares favorably to medical therapy in both cost and efficacy, particularly in patients with frequent symptomatic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Most of these studies evaluated patients with drug-refractory AVNRT, a population in whom RFA would be expected to perform well. However, RFA may also be cost-effective as initial therapy for patients with paroxysmal AVNRT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/42,44\">",
"     42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative efficacy and costs of RFA and medical therapy were compared in a series of 79 patients with newly documented SVT who were treated with either ablation or pharmacologic therapy, based upon patient preference [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/44\">",
"     44",
"    </a>",
"    ]. After a follow-up period of 12 months, both medication and ablation decreased the frequency of arrhythmia-related symptoms, but ablation was more likely to result in complete abolition of symptoms (74 versus 33 percent). Although ablation was initially more costly, the potential long-term costs were estimated to be similar after 9 to 12 years because of the cumulative cost of pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SETTINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patients with implanted devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, RFA is performed in patients who have a permanent pacemaker or implantable cardioverter-defibrillator (ICD). While transient elevations in pacing thresholds and diminished electrograms may be observed, these changes are rarely persistent or prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients have been reported to have AVNRT in a transplanted heart. The success rate for ablation therapy of this and other types of arrhythmias is high in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be significant gender-related differences in the utilization of RF ablation therapy for accessory pathways and AVNRT. In one report, women were referred for ablation therapy later, had had symptoms for a longer time, and had been treated with more antiarrhythmic drugs prior to ablation than men [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/48\">",
"     48",
"    </a>",
"    ]. There were no differences in the success, complications, or recurrence rates for ablation for men and women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining whether electrophysiology study and RFA are appropriate for a given patient is based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The frequency of the arrhythmia",
"     </li>",
"     <li>",
"      The significance of the symptoms",
"     </li>",
"     <li>",
"      Patient tolerance to medications",
"     </li>",
"     <li>",
"      Patient preference",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients who undergo EP study and ablation for SVT do not have a specific diagnosis at the time of the procedure. It difficult to distinguish AVNRT from other SVTs with certainty based upon the clinical and ECG characteristics alone. Because AVNRT is the most common of the PSVTs, the specific risks associated with AVNRT ablation (eg, AV block), should be presented to any patient undergoing EP study for an SVT without a clear diagnosis. Similarly, such patients should also be aware of the possibility that they may have another arrhythmia, which could affect the efficacy and risks of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Paroxysmal SVT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because RFA is generally safe, effective, and compares favorably to chronic medical therapy, it is increasingly favored by both clinicians and patients. However, because AVNRT is generally well-tolerated, it is important that patients fully understand and accept the small associated risks before undergoing the procedure.",
"   </p>",
"   <p>",
"    In 2003, the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) published guidelines for the management of patients with supraventricular arrhythmias, which included recommendations on the treatment of AVNRT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15304/abstract/5\">",
"     5",
"    </a>",
"    ]. Our approach to the chronic management of AVNRT, including selection of patients of RFA, is in general agreement with those guidelines. This approach is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H26#H26\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Chronic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency catheter ablation for AVNRT is a safe and effective procedure when performed in experienced centers with appropriate expertise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The general approach to the catheter ablation of AVNRT is based upon the concept of dual AV nodal pathways. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Underlying principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common approach to ablation of AVNRT involves targeting the slow pathway in the posterior third of Koch's triangle. This approach eliminates arrhythmia recurrence in up to 95 percent of patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Posterior approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most significant potential complication of RFA for AVNRT is the development of complete heart block, which occurs in approximately 1 percent of patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining whether RFA is appropriate for a given patient with known or suspected AVNRT is based upon several factors, including patient preference. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H26#H26\">",
"       \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Chronic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1669577369\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. David Wilber, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/1\">",
"      Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991; 324:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/2\">",
"      Janse MJ, Anderson RH, McGuire MA, Ho SY. \"AV nodal\" reentry: Part I: \"AV nodal\" reentry revisited. J Cardiovasc Electrophysiol 1993; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/3\">",
"      McGuire MA, Janse MJ, Ross DL. \"AV nodal\" reentry: Part II: AV nodal, AV junctional, or atrionodal reentry? J Cardiovasc Electrophysiol 1993; 4:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/4\">",
"      Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm 2004; 1:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/5\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/6\">",
"      Morady F. Catheter ablation of supraventricular arrhythmias: state of the art. J Cardiovasc Electrophysiol 2004; 15:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/7\">",
"      de Sisti A, Tonet J. Cryoablation of atrioventricular nodal reentrant tachycardia: a clinical review. Pacing Clin Electrophysiol 2012; 35:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/8\">",
"      Deisenhofer I, Zrenner B, Yin YH, et al. Cryoablation versus radiofrequency energy for the ablation of atrioventricular nodal reentrant tachycardia (the CYRANO Study): results from a large multicenter prospective randomized trial. Circulation 2010; 122:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/9\">",
"      McGuire MA, Bourke JP, Robotin MC, et al. High resolution mapping of Koch's triangle using sixty electrodes in humans with atrioventricular junctional (AV nodal) reentrant tachycardia. Circulation 1993; 88:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/10\">",
"      Fisher WG, Pelini MA, Bacon ME. Adjunctive intracardiac echocardiography to guide slow pathway ablation in human atrioventricular nodal reentrant tachycardia: anatomic insights. Circulation 1997; 96:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/11\">",
"      Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 1992; 327:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/12\">",
"      Haissaguerre M, Gaita F, Fischer B, et al. Elimination of atrioventricular nodal reentrant tachycardia using discrete slow potentials to guide application of radiofrequency energy. Circulation 1992; 85:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/13\">",
"      Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999; 99:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/14\">",
"      Clague JR, Dagres N, Kottkamp H, et al. Targeting the slow pathway for atrioventricular nodal reentrant tachycardia: initial results and long-term follow-up in 379 consecutive patients. Eur Heart J 2001; 22:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/15\">",
"      Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/16\">",
"      Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients with documented but noninducible paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1996; 28:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/17\">",
"      Hummel JD, Strickberger SA, Williamson BD, et al. Effect of residual slow pathway function on the time course of recurrences of atrioventricular nodal reentrant tachycardia after radiofrequency ablation of the slow pathway. Am J Cardiol 1995; 75:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/18\">",
"      Lindsay BD, Chung MK, Gamache MC, et al. Therapeutic end points for the treatment of atrioventricular node reentrant tachycardia by catheter-guided radiofrequency current. J Am Coll Cardiol 1993; 22:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/19\">",
"      Lee MA, Morady F, Kadish A, et al. Catheter modification of the atrioventricular junction with radiofrequency energy for control of atrioventricular nodal reentry tachycardia. Circulation 1991; 83:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/20\">",
"      Jazayeri MR, Hempe SL, Sra JS, et al. Selective transcatheter ablation of the fast and slow pathways using radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. Circulation 1992; 85:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/21\">",
"      Langberg JJ, Leon A, Borganelli M, et al. A randomized, prospective comparison of anterior and posterior approaches to radiofrequency catheter ablation of atrioventricular nodal reentry tachycardia. Circulation 1993; 87:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/22\">",
"      Pires LA, Huang SK, Mazzola F, Wagshal AB. Long-term outcome after radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia with the anterior-approach method. Am Heart J 1996; 132:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/23\">",
"      Goldberger J, Brooks R, Kadish A. Physiology of \"atypical\" atrioventricular junctional reentrant tachycardia occurring following radiofrequency catheter modification of the atrioventricular node. Pacing Clin Electrophysiol 1992; 15:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/24\">",
"      Verdino RJ, Burke MC, Kall JG, et al. Retrograde fast pathway ablation for atrioventricular nodal reentry associated with markedly prolonged PR intervals. Am J Cardiol 1999; 83:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/25\">",
"      Cooke PA, Wilber DJ. Radiofrequency catheter ablation of atrioventricular nodal reentry tachycardia utilizing nonfluoroscopic electroanatomical mapping. Pacing Clin Electrophysiol 1998; 21:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/26\">",
"      Engelstein ED, Stein KM, Markowitz SM, Lerman BB. Posterior fast atrioventricular node pathways: implications for radiofrequency catheter ablation of atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1996; 27:1098.",
"     </a>",
"    </li>",
"    <li>",
"     Lockwood D, Otomo K, Wang Z, et al. Electrophysiologic characteristics of atrioventricular nodal reentrant tachycardia: Implications for the reentrant circuit. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes DP, Jaliffe J (Eds), Saunders, Philadelphia 2004. p.537.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/28\">",
"      Jentzer JH, Goyal R, Williamson BD, et al. Analysis of junctional ectopy during radiofrequency ablation of the slow pathway in patients with atrioventricular nodal reentrant tachycardia. Circulation 1994; 90:2820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/29\">",
"      Skanes AC, Dubuc M, Klein GJ, et al. Cryothermal ablation of the slow pathway for the elimination of atrioventricular nodal reentrant tachycardia. Circulation 2000; 102:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/30\">",
"      Boulos M, Hoch D, Schecter S, et al. Age dependence of complete heart block complicating radiofrequency ablation of the atrioventricular nodal slow pathway. Am J Cardiol 1998; 82:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/31\">",
"      Lipscomb KJ, Zaidi AM, Fitzpatrick AP, Lefroy D. Slow pathway modification for atrioventricular node re-entrant tachycardia: fast junctional tachycardia predicts adverse prognosis. Heart 2001; 85:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/32\">",
"      Li YG, Gr&ouml;nefeld G, Bender B, et al. Risk of development of delayed atrioventricular block after slow pathway modification in patients with atrioventricular nodal reentrant tachycardia and a pre-existing prolonged PR interval. Eur Heart J 2001; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/33\">",
"      Natale A, Greenfield RA, Geiger MJ, et al. Safety of slow pathway ablation in patients with long PR interval: further evidence of fast and slow pathway interaction. Pacing Clin Electrophysiol 1997; 20:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/34\">",
"      Reithmann C, Hoffmann E, Gr&uuml;newald A, et al. Fast pathway ablation in patients with common atrioventricular nodal reentrant tachycardia and prolonged PR interval during sinus rhythm. Eur Heart J 1998; 19:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/35\">",
"      Basta MN, Krahn AD, Klein GJ, et al. Safety of slow pathway ablation in patients with atrioventricular node reentrant tachycardia and a long fast pathway effective refractory period. Am J Cardiol 1997; 80:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/36\">",
"      Kocovic DZ, Harada T, Shea JB, et al. Alterations of heart rate and of heart rate variability after radiofrequency catheter ablation of supraventricular tachycardia. Delineation of parasympathetic pathways in the human heart. Circulation 1993; 88:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/37\">",
"      Psychari SN, Theodorakis GN, Koutelou M, et al. Cardiac denervation after radiofrequency ablation of supraventricular tachycardias. Am J Cardiol 1998; 81:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/38\">",
"      Hamdan MH, Page RL, Wasmund SL, et al. Selective parasympathetic denervation following posteroseptal ablation for either atrioventricular nodal reentrant tachycardia or accessory pathways. Am J Cardiol 2000; 85:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/39\">",
"      Olsovsky MR, Belz MK, Stambler BS, et al. Selective slow pathway ablation does not alter enhancement of vagal tone on sinus and atrioventricular nodal function. Am J Cardiol 1996; 78:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/40\">",
"      Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/41\">",
"      Kalbfleisch SJ, Calkins H, Langberg JJ, et al. Comparison of the cost of radiofrequency catheter modification of the atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1992; 19:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/42\">",
"      Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 2002; 89:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/43\">",
"      Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med 2000; 133:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/44\">",
"      Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol 1998; 82:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/45\">",
"      Ellenbogen KA, Wood MA, Stambler BS. Acute effects of radiofrequency ablation of atrial arrhythmias on implanted permanent pacing systems. Pacing Clin Electrophysiol 1996; 19:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/46\">",
"      Kilborn MJ, McGuire MA. Radiofrequency catheter ablation of atrioventricular junctional (\"AV nodal\") reentrant tachycardia in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1998; 21:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/47\">",
"      Magnano AR, Garan H. Catheter ablation of supraventricular tachycardia in the transplanted heart: a case series and literature review. Pacing Clin Electrophysiol 2003; 26:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15304/abstract/48\">",
"      Dagres N, Clague JR, Breithardt G, Borggrefe M. Significant gender-related differences in radiofrequency catheter ablation therapy. J Am Coll Cardiol 2003; 42:1103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 939 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-DB4EA05A22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15304=[""].join("\n");
var outline_f14_60_15304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNDERLYING PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11043421\">",
"      RADIOFREQUENCY ABLATION VERSUS CRYOABLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMPORTANT ANATOMY AND TARGETING THE SITE OF ABLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Posterior approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anterior approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anatomic variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Atypical forms of AVNRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AV block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Risk factors for AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ABLATION VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patients with implanted devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669577369\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/939|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/35/1598\" title=\"figure 1\">",
"      Common slow fast AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/17/12562\" title=\"figure 2\">",
"      Anatomy of Koch's triangle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/31/26096\" title=\"figure 3\">",
"      Location of Koch's triangle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/15/18673\" title=\"figure 4\">",
"      Ablation sites for AVNRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/939|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?15/63/16373\" title=\"waveform 1A\">",
"      EP study tracings mapping slow AV nodal pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?4/62/5092\" title=\"waveform 1B\">",
"      EP study tracings RF ablation AVNRT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15305="Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome";
var content_f14_60_15305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15305/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15305/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15305/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/60/15305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction from the atria to the ventricles normally occurs via the atrioventricular node (AV)-His-Purkinje system. Patients with a preexcitation syndrome have an additional or alternative pathway, known as an accessory pathway, which directly connects the atria and ventricles and bypasses the AV node. In the Wolff-Parkinson-White (WPW) syndrome, AV conduction is through an AV bypass tract (the bundle of Kent). This results in earlier activation (preexcitation) of the ventricles than if the impulse had traveled through the AV node.",
"   </p>",
"   <p>",
"    Symptoms associated with the WPW syndrome are a result of arrhythmia with a rapid heart rate due, for example, to preexcited atrial fibrillation or atrial flutter with a rapid ventricular response. Symptoms range from mild palpitations to syncope and even sudden cardiac death due to ventricular fibrillation. Fortunately, the incidence of sudden death in patients with the WPW syndrome is quite low, ranging from 0 to 0.39 percent annually in several large case series, with the lowest risk seen in asymptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H8471569#H8471569\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Ventricular fibrillation and sudden death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the WPW syndrome are treated because of symptomatic arrhythmia or the risk of a life-threatening arrhythmia. Asymptomatic patients with the WPW electrocardiographic pattern are not treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pharmacologic therapies that are available. Nonpharmacologic therapies, including antitachycardia devices and catheter and surgical ablation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with preexcitation and symptomatic arrhythmias should be treated with catheter based radiofrequency ablation. Details of this procedure and rationale supporting this recommendation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are not candidates for ablation procedures, and for selected patients with rare, well-tolerated arrhythmias, antiarrhythmic therapy is an alternative. When antiarrhythmic drugs are used, the choice of agent is determined by the etiology of the arrhythmia and its electrophysiologic properties (",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    ). As an example, the pharmacologic treatment of atrioventricular reentrant tachycardia (AVRT) requires a drug that has its most potent depressant action on the \"weak link\" of the tachycardia circuit (most often the AV node). Thus, therapy may need to be guided by electrophysiologic testing to identify this link. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24025?source=see_link\">",
"     \"Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The electrocardiogram can define both the underlying arrhythmia and some of its features. For AVRT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the tachycardia has a narrow QRS complex (orthodromic AVRT), the antegrade limb (ie, the pathway that conducts the impulse to the ventricle) is the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system; in this setting, the delta wave seen during sinus rhythm is lost since antegrade conduction is not via the accessory pathway (ie, the ventricle is not preexcited).",
"     </li>",
"     <li>",
"      If the tachycardia has a wide QRS complex (antidromic AVRT), the antegrade limb is usually the accessory pathway. In this situation, the QRS complex during the tachycardia resembles the preexcited QRS complex during sinus rhythm, although it may be wider as it is maximally preexcited and not a fusion complex. An orthodromic AVRT may be associated with a wide QRS complex in the presence of a preexisting or rate-related functional bundle branch block. In this situation, the wide QRS complex does not resemble the preexcited QRS complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electrophysiologic testing while the patient is in sinus rhythm can be used to identify the weak link. Testing begins by performing atrial and ventricular pacing at incremental rates above the rate of the clinical tachycardia. The paced cycle lengths (the shorter the cycle length, the higher the heart rate) resulting in block within the antegrade (via atrial pacing) and retrograde (via ventricular pacing) limbs of the reentrant circuit are determined. The antegrade or retrograde limb having the greater difference between the tachycardia cycle length and the paced cycle length causing block in that pathway can be considered the \"strong\" limb of conduction, while the limb having the smaller difference can be considered the \"weak\" limb. In other words, the weak limb can be blocked at longer paced cycle lengths (ie, slower heart rates) because it has a longer refractory period",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more tenuous conduction properties.",
"   </p>",
"   <p>",
"    There is, however, a potential problem with directing drug therapy at the weak limb. Although a drug may have beneficial depressant effects on the weak limb, it may also lengthen the refractory period of the strong limb. If the strong limb is the site of the unidirectional block necessary for the development of reentry, the result may be widening of the tachycardia induction zone, an increased probability that spontaneous atrial or ventricular premature beats (APBs and VPBs) will trigger AVRT, and a reentrant circuit that maintains a more frequently occurring, if not incessant, tachycardia at a slower rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ORTHODROMIC AV REENTRANT TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AV node is the site of antegrade conduction and is usually the weak link in an orthodromic AVRT (OAVRT). Thus, relatively specific therapies that lengthen AV nodal refractoriness and depress its conduction can block the impulse within the node and terminate and prevent the tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maneuvers that increase vagal tone, such as carotid sinus massage and the Valsalva maneuver, and depress AV nodal function may be sufficient to cause AV node block and tachycardia termination (",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/2\">",
"     2",
"    </a>",
"    ]. If these measures are ineffective, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or adenosine are the drugs of choice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      at a dose of up to 15 mg given as 5 mg boluses every two to three minutes is effective for acute termination of OAVRT, provided that the patient is not profoundly hypotensive or suffering from heart failure associated with severely depressed ventricular systolic function rather than the rapid heart rate (",
"      <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39831?source=see_link\">",
"       \"Calcium channel blockers in the treatment of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous adenosine is as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      for acutely terminating OAVRT [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Its ultrashort duration of action makes it a preferred agent before resorting to emergent DC cardioversion in the patient whose hemodynamic state is more tenuous. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"       \"Cardioversion for specific arrhythmias\"",
"      </a>",
"      .) However, adenosine has the potential to transiently increase atrial vulnerability to atrial fibrillation (AF), a potentially serious proarrhythmic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/8\">",
"       8",
"      </a>",
"      ], and cause atrial ectopy that can reinitiate OAVRT after acute tachycardia termination [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/5,9,10\">",
"       5,9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Agents of second choice include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and the beta blockers approved for intravenous administration (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    ). Procainamide depresses conduction and prolongs refractoriness in atrial and ventricular myocardium, accessory pathways, and the His-Purkinje system, while having no effect or causing slight shortening of AV nodal refractory period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It is the drug of choice if the OAVRT presents as a wide QRS complex tachycardia due to functional or preexisting chronic bundle branch block or the diagnosis of OAVRT is in doubt. Intravenous procainamide is the safest, if not most effective, drug to administer for acute treatment of a wide QRS complex tachycardia of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    enhances vagal tone and can depress conduction through the AV node. However, its prolonged time to onset of action and peak effect, even when given intravenously, coupled with low potency make it a less attractive drug in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    are not approved in the United States for therapy of supraventricular tachyarrhythmias. Although amiodarone is an effective agent for acute termination of OAVRT, it has a role only in the rare setting in which other therapies, including cardioversion, are ineffective. Amiodarone prolongs the refractoriness of all cardiac tissue but it is possible that its effect when given intravenously is mediated by beta blockade of the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    also prolongs the refractoriness of atrial and ventricular myocardium and the accessory pathway. In one study of 51 patients the drug prevented the reinduction of OAVRT during electrophysiologic study in 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic therapy for prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of an antiarrhythmic drug in preventing OAVRT is related to its ability to alter the electrophysiologic properties of the circuit, rendering it incapable of sustaining reentry. Antiectopic activity to decrease the number of arrhythmia triggers (eg, APBs and VPBs) is another desirable effect. The selection of an effective antiarrhythmic drug should be based upon electrophysiologic testing which establishes the effect of the drug on the electrophysiologic properties of the various parts of the reentrant circuit and on the ability to induce the arrhythmia.",
"   </p>",
"   <p>",
"    Chronic drug therapy usually requires continuous dosing at regular intervals for an indefinite period of time (",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    ). However, there are patients with infrequent episodes of OAVRT that cause no or only mild symptoms who may be served equally well by an intermittent, acute oral drug regimen or \"cocktail\" therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/19\">",
"     19",
"    </a>",
"    ]. Drugs that can be used in this way include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    (600 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    (300 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    (1500 mg), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    (450 mg).",
"   </p>",
"   <p>",
"    Since patients requiring chronic drug treatment are potentially committed to indefinite antiarrhythmic drug prophylaxis, the optimum drug must have both a high efficacy rate and a low risk for causing adverse effects and noncardiac organ toxicity. Cardiac toxicity, especially arrhythmia aggravation, is less of an acute concern in the absence of structural heart disease, but the risk may ultimately need to be confronted as the patient ages.",
"   </p>",
"   <p>",
"    The class IC antiarrhythmic drugs possess the most favorable",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio and are the drugs of choice for OAVRT prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. An important exception is the presence of known coronary disease, a setting in which class IC drugs can increase mortality due to proarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    have been approved for prevention of paroxysmal supraventricular tachyarrhythmias, including OAVRT. Propafenone has a potential advantage since it also has mild beta blocking activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Agents with AV nodal-specific activity (beta blockers, calcium channel blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) are second-line drugs for chronic suppression of OAVRT. They may be inadequate as monotherapy because of their inability to directly slow conduction and increase antegrade or retrograde refractoriness in the accessory pathway; in addition, they do not reduce the frequency of arrhythmia-triggering APBs and VPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/3,4,10,12\">",
"     3,4,10,12",
"    </a>",
"    ]. AV nodal blocking drugs should not be given in patients who have documented atrial fibrillation or flutter in addition to OAVRT. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Atrial fibrillation'",
"    </a>",
"    below.) These drugs may, however, be a useful adjunct to a class I drug. The beta blockers may be of particular benefit since they prevent catecholamine reversal of drug effect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The class IA antiarrhythmic drugs lengthen antegrade and retrograde refractoriness and slow conduction in the accessory pathway; prior to the availability of the class IC agents they were the agents of choice for suppressing OAVRT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/14,26,27\">",
"     14,26,27",
"    </a>",
"    ]. However, these drugs are less potent than the class IC drugs, they only minimally lengthen AV node refractoriness, and they have a substantial risk of causing serious organ toxicity and intolerable noncardiac adverse effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has multiple electrophysiologic effects that make it effective in suppressing OAVRT including beta blocking activity, class III effects to prolong action potential repolarization, blockade of the fast sodium and slow calcium inward currents, and suppression of ectopic beats [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .) These effects result in slowing of impulse conduction and lengthening of refractoriness in both the bypass tract and the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    would seem to be an ideal drug for suppressing OAVRT. However, it has a number of common adverse effects, including pulmonary and hepatic toxicity, which is a concern for patients with WPW who are often young and may require many years of therapy. Despite these side effects, drug discontinuation during long-term therapy is uncommon, particularly when low maintenance doses of 200 to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Less serious adverse effects which occur in up to 90 percent of patients can affect the quality of life, resulting in withdrawal of drug in almost 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    is another drug that can prevent OAVRT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, an incidence of torsades de pointes as high as 4 percent raises concern about long-term safety. This risk seems greatest during the acute dose-titration phase of therapy in patients with advanced structural heart disease and life-threatening ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTIDROMIC AV REENTRANT TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An antidromic AV reentrant tachycardia (AAVRT), in which the antegrade limb uses the accessory pathway, presents with a wide QRS complex. Prior to therapy, it must be distinguished from other causes of a wide QRS complex tachycardia, primarily ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous drug of choice for acute treatment to terminate AAVRT is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    . Even if it does not result in tachycardia termination, intravenous procainamide will usually slow the tachycardia rate and improve the hemodynamic state (",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although retrograde AV node conduction is usually the weak link during AAVRT, intravenously administered AV node-specific blocking drugs such as beta blockers, calcium channel blockers, adenosine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    should be",
"    <strong>",
"     avoided",
"    </strong>",
"    unless the tachycardia is",
"    <strong>",
"     definitely known",
"    </strong>",
"    to be AAVRT. If the diagnosis is not certain, the patient should be considered to have an undiagnosed wide QRS tachycardia; of particular concern is ventricular tachycardia, which can become hemodynamically unstable or even degenerate into ventricular fibrillation following administration of one of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs should also be avoided in patients with WPW who have atrial fibrillation, since blocking the AV node will promote conduction down the accessory pathway. Another problem is that AAVRT can also degenerate into AF following drug administration, especially with adenosine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/5\">",
"     5",
"    </a>",
"    ]. In either case, inhibition of AV node conduction may enhance the preexcited ventricular rate response. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Avoidance of AV nodal blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic therapy for prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablation of the accessory pathway is the preferred therapy for chronic prevention of AAVRT. An important concern about long-term medical therapy of this arrhythmia is the potential for AF. The accessory pathway, which is the antegrade limb, is also capable of antegrade preexcited conduction during AF.",
"   </p>",
"   <p>",
"    The selection of an effective antiarrhythmic drug should be based upon the effect of the drug on the electrophysiologic properties of the various parts of the reentrant circuit and on the ability to induce the arrhythmia. The AV nodal blocking agents, beta blockers, calcium channel blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    because of the possible occurrence of atrial fibrillation with accelerated conduction down the accessory pathway. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Avoidance of AV nodal blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The class IC drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are the agents of choice in the absence of other contraindications, which include the presence of underlying heart disease and myocardial ischemia (",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    ). These drugs may increase mortality in patients with known coronary disease due to proarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/24\">",
"     24",
"    </a>",
"    ]. Class IA drugs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    are also effective but are less desirable because of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of acute drug therapy for preexcited AF are prompt control of the ventricular response and stabilization of the hemodynamic state. Treatment of preexcited AF requires a parenteral drug with rapid onset of action that lengthens antegrade refractoriness and slows conduction in both the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system and the accessory pathway.",
"   </p>",
"   <p>",
"    The approach discussed below is generally in agreement with guidelines published in 2000 by the International Liaison Committee on Resuscitation (ILCOR) (",
"    <a class=\"graphic graphic_table graphicRef80760 \" href=\"UTD.htm?34/25/35228\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/36\">",
"     36",
"    </a>",
"    ] and the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology on guidelines on atrial fibrillation (",
"    <a class=\"graphic graphic_table graphicRef68805 \" href=\"UTD.htm?13/49/14108\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"     \"Overview of the acute management of tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The class IC antiarrhythmic drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    and the class III agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    are effective when used in this setting, but the parenteral formulations of these drugs are not approved for use in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Thus, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    is the drug of choice for acute therapy in the United States (",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80760 \" href=\"UTD.htm?34/25/35228\">",
"     table 2",
"    </a>",
"    ). It may terminate AF because of its effect on atrial myocardium. However, even if AF persists, the ventricular response rate usually slows due to effects on refractoriness and conduction in the accessory pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    , a class III antiarrhythmic drug that is only available for intravenous administration, is also useful for acute termination of AF and atrial flutter. Since it prolongs the refractoriness of the AV node, His-Purkinje system, and accessory pathway, it has a role in WPW [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In one series of 22 patients with AF during an electrophysiologic study, ibutilide prolonged the shortest preexcited RR interval and terminated the arrhythmia in 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=see_link\">",
"     \"Therapeutic use of ibutilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not approved for acute therapy of AF, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be effective for reverted AF in WPW or may slow the ventricular rate as a result of its effect on accessory pathway refractoriness and conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Avoidance of AV nodal blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV node-specific antiarrhythmic drugs that are normally used to control the ventricular rate during nonpreexcited AF are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62762 \" href=\"UTD.htm?23/3/23612\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68805 \" href=\"UTD.htm?13/49/14108\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous beta blockers when used alone do not increase accessory pathway refractoriness; furthermore, as noted above, inhibition of AV node conduction may enhance the preexcited ventricular rate response by decreasing the degree of concealed retrograde conduction into the accessory pathway. An accessory pathway with a short intrinsic antegrade refractory period that was initially competing with the AV node could then become the dominant route for rapid, antegrade conduction.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is also contraindicated because of blockade of AV nodal conduction and its unpredictable effect on accessory pathway refractoriness [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/44\">",
"       44",
"      </a>",
"      ]. Digoxin's vagomimetic action lengthens AV node refractoriness and reduces concealed retrograde conduction into the accessory pathway. In addition, a comparatively slow time to onset of action and peak effect make digoxin an unacceptable drug to use when rapid ventricular rate control is required.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      is perhaps the",
"      <strong>",
"       most dangerous",
"      </strong>",
"      AV nodal blocker to administer during preexcited AF [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. Intravenous verapamil lengthens AV node refractoriness, decreases concealed conduction into the accessory pathway, and has no direct effect on the accessory pathway. Myocardial contractility and systemic vascular resistance are also reduced; these effects may cause a reflex increase in already elevated sympathetic tone that further shortens accessory pathway refractoriness. Precipitation of cardiac arrest by degeneration of preexcited AF to ventricular fibrillation has been reported after intravenous verapamil administration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous adenosine causes an effect similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and also can precipitate ventricular fibrillation. Adenosine is unlikely to convert AF and has only a transient effect on the AV node. Its use is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in AF.",
"   </p>",
"   <p>",
"    As mentioned above, AV nodal blockers are also contraindicated in patients with a wide QRS complex tachycardia that is not known with certainty to be AAVRT. If the arrhythmia is a ventricular tachycardia, it can become hemodynamically unstable or even degenerate into ventricular fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic therapy for prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drug selected for prevention of intermittent AF in the WPW syndrome should possess antifibrillatory activity on the atrial myocardium, antiectopic activity to suppress both APBs and VPBs that can induce AF, and should prevent AVRT since the latter can subsequently degenerate into AF. The drug must also lengthen refractoriness in both the accessory pathway and the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system to provide adequate background protection against a rapid ventricular response should AF intermittently occur.",
"   </p>",
"   <p>",
"    Class IC drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ) possess the best electrophysiologic profile for achieving these goals if no cardiac contraindications exist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Class IA drugs are less potent and have more noncardiac adverse effects as previously noted.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is useful when class IC and IA drugs are ineffective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    not tolerated and when ablation therapy is inappropriate or has failed (",
"    <a class=\"graphic graphic_table graphicRef72357 \" href=\"UTD.htm?7/9/7323\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"       \"Patient information: Wolff-Parkinson-White syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=see_link\">",
"       \"Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use the following approach to medical therapy in patients with symptomatic arrhythmias due to the WPW syndrome. These recommendations are in general agreement with guidelines published in 2006 by the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology atrial fibrillation and sudden cardiac death guidelines (",
"    <a class=\"graphic graphic_table graphicRef68805 \" href=\"UTD.htm?13/49/14108\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72357 \" href=\"UTD.htm?7/9/7323\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/37,52\">",
"     37,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy is indicated for all patients who experience symptomatic arrhythmias, regardless of the etiology. Therapy is particularly important for patients with rapid conduction over the accessory pathway during atrial fibrillation or atrial flutter. The",
"      <strong>",
"       treatment of choice",
"      </strong>",
"      for these patients is radiofrequency catheter ablation of the accessory pathway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"       \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who experience only infrequent and minimally symptomatic OAVRT may consider \"cocktail\" pharmacologic treatment: large single-dose pharmacologic therapy, taken when needed for an arrhythmic event, along with properly taught self-performed vagomimetic maneuvers to assist in terminating arrhythmia episodes. Drugs that can be administered in this fashion include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      (600 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      (300 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      (1500 mg), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      (450 mg). In some patients",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (160 mg) or a beta blocker may be effective. However, these patients should first undergo an electrophysiologic study to assure that the antegrade conduction properties of the accessory pathway are not potentially malignant; performing atrial pacing using a transesophageal electrode might offer a less invasive method for performing this assessment.",
"     </li>",
"     <li>",
"      AV nodal blocking drugs are contraindicated in patients with WPW who have atrial fibrillation or a wide QRS complex tachycardia that is not known with certainty to be AAVRT. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Avoidance of AV nodal blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients whose life expectancy is severely limited by other diseases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who are elderly are probably best treated with chronic pharmacologic therapy, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , guided by electrophysiologic testing. However, relatively healthy elderly patients should not be denied radiofrequency catheter ablation because of age alone if they experience highly symptomatic arrhythmia that responds poorly to medical treatment.",
"     </li>",
"     <li>",
"      Asymptomatic patients are likely to remain asymptomatic and conduction via the accessory pathway may disappear spontaneously. A cost-effectiveness analysis of radiofrequency ablation supported the practice of observing asymptomatic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/53\">",
"       53",
"      </a>",
"      ]. Nevertheless, electrophysiologic evaluation and radiofrequency ablation is advisable for certain patients who have an accessory pathway with a very short refractory period because of the potential for rapid ventricular rates during atrial fibrillation or atrial flutter. Included in this group are patients in high-risk professions, professions involving risk to others, athletes, and those with a family history of sudden death (",
"      <a class=\"graphic graphic_table graphicRef72357 \" href=\"UTD.htm?7/9/7323\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/60/15305/abstract/52,54\">",
"       52,54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"       \"Arrhythmia in athletes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/1\">",
"      Jackman WM, Friday KJ, Fitzgerald DM, et al. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Am J Cardiol 1988; 62:8L.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/2\">",
"      Mehta D, Wafa S, Ward DE, Camm AJ. Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet 1988; 1:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/3\">",
"      Rinkenberger RL, Prystowsky EN, Heger JJ, et al. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation 1980; 62:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/4\">",
"      Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 1980; 93:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/5\">",
"      Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/6\">",
"      diMarco JP, Sellers TD, Lerman BB, et al. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 1985; 6:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/7\">",
"      DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/8\">",
"      Exner DV, Muzyka T, Gillis AM. Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine. Ann Intern Med 1995; 122:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/9\">",
"      Dougherty AH, Gilman JK, Wiggins S, et al. Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine. Pacing Clin Electrophysiol 1993; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/10\">",
"      DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990; 113:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/11\">",
"      Kowey PR, Friehling TD, Marinchak RA. Electrophysiology of beta blockers in supraventricular arrhythmias. Am J Cardiol 1987; 60:32D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/12\">",
"      Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group. Am Heart J 1986; 111:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/13\">",
"      Mandel WJ, Laks MM, Obayashi K, et al. The Wolff-Parkinson-White syndrome: pharmacologic effects of procaine amide. Am Heart J 1975; 90:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/14\">",
"      Wellens HJ. The wide QRS tachycardia. Ann Intern Med 1986; 104:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/15\">",
"      Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/16\">",
"      Josephson ME, Caracta AR, Ricciutti MA, et al. Electrophysiologic properties of procainamide in man. Am J Cardiol 1974; 33:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/17\">",
"      Gomes JA, Kang PS, Hariman RJ, et al. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone. Am Heart J 1984; 107:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/18\">",
"      Cobbe SM, Campbell RW, Camm AJ, et al. Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart 2001; 86:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/19\">",
"      Margolis B, DeSilva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980; 45:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/20\">",
"      Kim SS, Lal R, Ruffy R. Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol 1986; 58:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/21\">",
"      Ward DE, Jones S, Shinebourne EA. Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. Am J Cardiol 1986; 57:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/22\">",
"      Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 1987; 9:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/23\">",
"      Musto B, D'Onofrio A, Cavallaro C, Musto A. Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation 1988; 78:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/24\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/25\">",
"      Manolis AS, Estes NA 3rd. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. Am J Cardiol 1989; 64:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/26\">",
"      Wellens HJ, Durrer D. Effect of procaine amide, quinidine, and ajmaline in the Wolff-Parkinson-White syndrome. Circulation 1974; 50:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/27\">",
"      Kerr CR, Prystowsky EN, Smith WM, et al. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. Circulation 1982; 65:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/28\">",
"      Rosenbaum MB, Chiale PA, Ryba D, Elizari MV. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol 1974; 34:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/29\">",
"      Wellens HJ, Lie KI, B&auml;r FW, et al. Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol 1976; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/30\">",
"      Feld GK, Nademanee K, Weiss J, et al. Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes. J Am Coll Cardiol 1984; 3:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/31\">",
"      Kowey PR, Friehling TD, Marinchak RA, et al. Safety and efficacy of amiodarone. The low-dose perspective. Chest 1988; 93:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/32\">",
"      Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/33\">",
"      Mason JW. Amiodarone. N Engl J Med 1987; 316:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/34\">",
"      Mitchell LB, Wyse DG, Duff HJ. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 76:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/35\">",
"      Kunze KP, Schl&uuml;ter M, Kuck KH. Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 75:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/36\">",
"      Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: 7D: the tachycardia algorithms. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102:I158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/37\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/38\">",
"      Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989; 64:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/39\">",
"      Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/40\">",
"      Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/41\">",
"      Krahn AD, Klein GJ, Yee R. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 2001; 24:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/42\">",
"      Varriale P, Sedighi A, Mirzaietehrane M. Ibutilide for termination of atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1999; 22:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/43\">",
"      Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001; 104:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/44\">",
"      Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977; 56:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/45\">",
"      Garratt C, Antoniou A, Ward D, Camm AJ. Misuse of verapamil in pre-excited atrial fibrillation. Lancet 1989; 1:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/46\">",
"      Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982; 65:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/47\">",
"      McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med 1986; 104:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/48\">",
"      Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 1988; 62:35D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/49\">",
"      Antman EM, Beamer AD, Cantillon C, et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/50\">",
"      Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984; 54:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/51\">",
"      Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. Am Heart J 1988; 115:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/52\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/53\">",
"      Hogenhuis W, Stevens SK, Wang P, et al. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. Circulation 1993; 88:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15305/abstract/54\">",
"      Steinbeck G. Should radiofrequency current ablation be performed in asymptomatic patients with the Wolff-Parkinson-White syndrome? Pacing Clin Electrophysiol 1993; 16:649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 996 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15305=[""].join("\n");
var outline_f14_60_15305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ORTHODROMIC AV REENTRANT TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute termination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic therapy for prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTIDROMIC AV REENTRANT TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute termination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic therapy for prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ATRIAL FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Avoidance of AV nodal blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic therapy for prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/3/23612\" title=\"table 1\">",
"      Drug Rx arrhythmias WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/25/35228\" title=\"table 2\">",
"      ACLS AF rate rhythm control II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/49/14108\" title=\"table 3\">",
"      ACC AHA ESC manage AF in WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/9/7323\" title=\"table 4\">",
"      ACCAHAESC WPW abl",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39831?source=related_link\">",
"      Calcium channel blockers in the treatment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24025?source=related_link\">",
"      Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=related_link\">",
"      Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=related_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=related_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=related_link\">",
"      Therapeutic use of ibutilide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15306="Treatment of bacterial meningitis caused by specific pathogens in adults";
var content_f14_60_15306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of bacterial meningitis caused by specific pathogens in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15306/contributors\">",
"     Allan R Tunkel, MD, PhD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15306/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/60/15306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/60/15306/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/60/15306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis is a medical emergency, and immediate steps must be taken to establish the specific cause and initiate effective therapy. The mortality rate of untreated disease approaches 100 percent and, even with optimal therapy, there is a high failure rate.",
"   </p>",
"   <p>",
"    The possible presence of bacterial meningitis is suggested by the symptoms of fever, altered mental status, headache, and nuchal rigidity. Although one or more of these findings are absent in many patients with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], virtually all patients (99 to 100 percent) have at least one of the classic triad of fever, neck stiffness, and altered mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prevention of bacterial meningitis caused by specific pathogens will be reviewed here. The epidemiology, pathogenesis, clinical features, diagnosis, initial management, and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for the treatment of bacterial meningitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link\">",
"     \"Epidemiology of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38549?source=see_link\">",
"     \"Pathogenesis and pathophysiology of bacterial meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of general principles of antibiotic therapy in patients with bacterial meningitis. The most important initial issues are avoidance of delay in administering therapy and the choice of drug regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'General principles of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy, along with adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    when indicated, should be initiated immediately after the performance of the lumbar puncture (LP) or, if a computed tomography (CT) scan of the head is to be performed before LP, immediately after blood cultures are obtained. Adjunctive dexamethasone should be given shortly before or at the same time as the first dose of antibiotics, when indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Avoidance of delay'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic selection must be empiric immediately after CSF is obtained or when lumbar puncture is delayed. In such patients, antibiotic therapy needs to be directed at the most likely bacteria based upon patient age and underlying comorbid disease (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Regimens based upon Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than empiric therapy, intravenous antibiotics should be directed at the presumed pathogen if the Gram stain is diagnostic (",
"    <a class=\"graphic graphic_table graphicRef75922 graphicRef60707 \" href=\"UTD.htm?5/11/5310\">",
"     table 1B-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the CSF findings are consistent with the diagnosis of acute bacterial meningitis, but the Gram stain is negative, empiric antibiotic therapy should be continued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Regimens based upon gram stain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antibiotic regimen should be modified further, when indicated, based on the CSF culture and susceptibility results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the general limitation in antibiotic penetration into the CSF, all patients should be treated with intravenous antibiotics. Oral antibiotics should be avoided since the dose and tissue concentrations tend to be considerably lower than with parenteral agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adjunctive dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent neurologic sequelae, such as hearing loss and focal neurologic deficits, are not uncommon in survivors of bacterial meningitis, particularly patients with pneumococcal meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early intravenous administration of glucocorticoids (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) has been evaluated as adjunctive therapy in an attempt to diminish the rate of hearing loss, other neurologic complications, and mortality. Based upon clinical trial data from Europe, the main indication for dexamethasone therapy in adults is known or suspected pneumococcal meningitis. Since the etiology of bacterial meningitis is not usually known at the time of treatment initiation, dexamethasone is administered to patients in the developed world with suspected bacterial meningitis in whom the organism is unknown. Dexamethasone should only be continued if the CSF Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the CSF or blood cultures reveal S. pneumoniae.",
"   </p>",
"   <p>",
"    Since the entry of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    into the CSF may be reduced by the decrease in inflammation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is sometimes added in patients receiving dexamethasone. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link&amp;anchor=H9#H9\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\", section on 'Antibiotic regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy in the developing world varies with the patient population. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THERAPY FOR SPECIFIC PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of various pathogens in bacterial meningitis varies by region of the world. Among adults with bacterial meningitis in the United States, Streptococcus pneumoniae and Neisseria meningitidis are the most common infecting organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Community-acquired'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following treatment recommendations are in agreement with the 2004 Infectious Diseases Society of America (IDSA) guidelines for the management of bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ]. Since there have been no randomized trials regarding the therapy of specific causes of bacterial meningitis, treatment recommendations are based upon in vitro susceptibility and pharmacodynamic data, as well as accumulated clinical experience.",
"   </p>",
"   <p>",
"    Directed therapy against a specific organism is recommended when the clinical presentation and results of the CSF Gram stain are unequivocal (",
"    <a class=\"graphic graphic_table graphicRef75922 \" href=\"UTD.htm?10/57/11164\">",
"     table 1C",
"    </a>",
"    ) or the cultures are already positive (",
"    <a class=\"graphic graphic_table graphicRef81209 \" href=\"UTD.htm?11/55/12158\">",
"     table 1D",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ]. If, on the other hand, empiric therapy is begun, the regimen should be adjusted, if necessary once the culture results are available (",
"    <a class=\"graphic graphic_table graphicRef81209 \" href=\"UTD.htm?11/55/12158\">",
"     table 1D",
"    </a>",
"    ). Recommended dosages for use in patients with normal renal and hepatic function are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef60707 \" href=\"UTD.htm?17/45/18141\">",
"     table 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The duration of therapy for meningitis in adults has not been subjected to rigorous trials in the United States or other developed countries. The recommendations in the following sections reflect general consensus and are fairly conservative. However, a longer course may be warranted when complicating features are present or the clinical response is unusually slow. On the other hand, shorter courses (eg, single doses of depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    or conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) have been successful in the management of epidemic meningococcal meningitis in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Empiric treatment during epidemics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Streptococcus pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. pneumoniae is the most common cause of meningitis in adults, particularly in elderly adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. In a review of 248 patients with bacterial meningitis seen in 1995 in acute care hospitals in 22 counties in four states in the United States, S. pneumoniae accounted for 60 percent of cases in adults up to age 60 and almost 70 percent in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Community-acquired'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rates of pneumococcal meningitis have been reported to have decreased among both children and adults since the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in children, there has also been a concerning increase in meningitis caused by pneumococcal serotypes not in the vaccine (specifically serotypes 19A, 22F, and 35B). Thus, there is a need for continued monitoring of the serotypes causing invasive infection. With the licensure of the 13-valent pneumococcal conjugate vaccine in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/8\">",
"     8",
"    </a>",
"    ], further declines in the incidence of pneumococcal meningitis may be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link&amp;anchor=H3#H3\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\", section on 'Impact of childhood vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, the conventional approach to the treatment of pneumococcal meningitis was the administration of penicillin alone for two weeks at a dose of four million units intravenously every four hours in patients with normal renal function. Good results were also obtained with a third-generation cephalosporin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the widespread emergence of penicillin-resistant pneumococcus has made penicillin an inappropriate therapy without proof of in vitro susceptibility. Although many third-generation cephalosporins have good in vitro activity against strains of pneumococcus that have intermediate susceptibility to penicillin (minimum inhibitory concentration [MIC] 0.12 to 1.0",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    according to the cutoffs used prior to 2008, reports have raised the possibility of clinical failure when cephalosporin resistance coexists with penicillin resistance (",
"    <a class=\"graphic graphic_table graphicRef63881 \" href=\"UTD.htm?16/13/16605\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/9\">",
"     9",
"    </a>",
"    ]. In 2008, the Clinical and Laboratory Standards Institute removed the \"intermediate\" susceptibility category (MIC 0.12 to 1",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    for the penicillin breakpoints of meningeal isolates of S. pneumoniae, such that all meningeal isolates with an MIC &ge;0.12 are considered resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     First-line regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial empiric therapy of S. pneumoniae in patients with normal renal function includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 to 12 hours)",
"    <strong>",
"     plus",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV every 12 hours) OR",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g IV every four to six hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with isolates that are susceptible to penicillin (MIC &le;0.06",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    penicillin (4 million units IV every 4 hours) can be used instead of a third-generation cephalosporin, although it is also reasonable to continue therapy with a third-generation cephalosporin given the excellent efficacy, convenient dosing, and affordability of these agents. If the isolate is resistant to penicillin (MIC &ge;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    but is susceptible to third-generation cephalosporins (minimal inhibitory concentration [MIC] &lt;1.0",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g IV every four to six hours) are the preferred drugs. Although some retrospective studies have advocated cephalosporin monotherapy for organisms with MICs up to 1.0",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for cefotaxime or ceftriaxone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], it seems more prudent to use the lower breakpoint (ie, less than 1.0",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    , in combination with a third-generation cephalosporin, should be continued if there is penicillin resistance (MIC &ge;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    and an MIC &gt;1.0",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    to third-generation cephalosporins (",
"    <a class=\"graphic graphic_table graphicRef81209 \" href=\"UTD.htm?11/55/12158\">",
"     table 1D",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is erratic in its penetration into the CSF and may be ineffective as monotherapy in pneumococcal meningitis. Nevertheless, it is recommended that vancomycin (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 to 12 hours if renal function is normal) be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    in the initial treatment of pneumococcal meningitis until susceptibility results are available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ]. The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Serum trough concentrations of vancomycin should range from 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients receiving adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , the diminished CSF inflammatory response after dexamethasone administration may reduce CSF",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    penetration and delay CSF sterilization, possibly worsening outcomes. However, in a study of 14 patients, the administration of intravenous vancomycin (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose, followed by a continuous infusion of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) led to mean serum and CSF vancomycin concentrations of 25.5 and 7.2",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    respectively, indicating that significant CSF concentrations can be attained with appropriate dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/12\">",
"     12",
"    </a>",
"    ]. If dexamethasone is given, some experts recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (600 mg orally once daily) in addition to vancomycin since its CSF penetration is unaffected by dexamethasone, and it is synergistic with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    against beta-lactam resistant S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual duration of therapy for pneumococcal meningitis is 10 to 14 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    (1.5 g intravenously every six hours) has been used in patients with pneumococcal meningitis who are allergic to penicillin and cephalosporins. However, many penicillin-resistant strains are also somewhat resistant to chloramphenicol killing (despite in vitro tests that show inhibition) and treatment failures of meningitis due to penicillin-resistant S. pneumoniae have occurred when chloramphenicol is used. One series evaluated 25 children with pneumococcal meningitis who had in vitro sensitivity to and were treated with chloramphenicol; 20 (80 percent) had an unsatisfactory outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The older fluoroquinolones have generally lacked sufficient activity against S. pneumoniae to warrant their use in the therapy of pneumococcal meningitis, but the newer fluoroquinolones such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    have shown excellent in vitro activity and efficacy in animal models of pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, clinical data are sparse. One fluoroquinolone, trovafloxacin, was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , in a multicenter, randomized trial of 311 children with bacterial meningitis in which 27 percent of cases had pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/17\">",
"     17",
"    </a>",
"    ]. The overall efficacy (CSF sterilization and clinical success) of both treatment groups was similar. Trovafloxacin is no longer utilized because of its association with serious liver toxicity, although these results suggest the potential usefulness of newer fluoroquinolones in the treatment of bacterial meningitis.",
"   </p>",
"   <p>",
"    Although there are not sufficient data to recommend fluoroquinolones as part of the routine treatment of pneumococcal meningitis, this class is sometimes used in patients with serious allergies to cephalosporins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . If it is not possible to use cephalosporins or vancomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    is probably the best choice as a second agent given its excellent in vitro activity and CSF penetration. For example, in a patient with a serious cephalosporin allergy, moxifloxacin should be used in combination with vancomycin. Conversely, in a patient with a serious vancomycin allergy, moxifloxacin should be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H22#H22\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Beta-lactam allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neisseria meningitidis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal meningitis occurs most commonly in children and young adults. However, it also accounts for approximately 20 percent of cases of bacterial meningitis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Community-acquired'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Third-generation cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , should be used to treat suspected (eg, Gram stain with gram-negative diplococci) or culture-proven meningococcal infection prior to susceptibility results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ]. If the organism is proven to be penicillin-susceptible, the treatment can then be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    . The treatment of meningococcal meningitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A seven day duration of therapy is adequate for meningococcal meningitis. However, there may still be nasopharyngeal colonization with the infecting strain. As a result, the index patient may need to take an agent that eradicates colonization (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) to avoid transmission to others. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Droplet precautions should be used for 24 hours after starting effective antimicrobial therapy in patients with suspected or confirmed Neisseria meningitidis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H12#H12\">",
"     \"General principles of infection control\", section on 'Droplet precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Haemophilus influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haemophilus influenzae type b meningitis has decreased markedly in children following widespread vaccination of infants. However, strains other than type b continue to cause occasional invasive infection (including meningitis) in children and adults. In the review cited above of bacterial meningitis in the United States in 1995, H. influenzae accounted for 7 percent of cases in adults. Only 10 percent of adult H. influenzae meningitis cases were caused by serotype b strains; the remainder were caused by types a, e, and f [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evolution of treatment recommendations for H. influenzae type b infection has paralleled changes in this organism's susceptibility profile. The results of numerous clinical trials have shown that third-generation cephalosporins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    are as effective for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    -resistant as for ampicillin-susceptible organisms.",
"   </p>",
"   <p>",
"    A third-generation cephalosporin (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) is the drug of choice for H. influenzae meningitis. The best data supporting this recommendation come from randomized trials in children. One such trial compared ceftriaxone with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (a second-generation cephalosporin with good CSF penetration) in children with bacterial meningitis, which was due to H. influenzae in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/19\">",
"     19",
"    </a>",
"    ]. Ceftriaxone was significantly more likely to sterilize the CSF at 24 hours (100 versus 90 percent) and was associated with a lesser likelihood of hearing impairment at the conclusion of therapy (11 versus 18 percent). Virtually identical findings were noted in a second randomized trial comparing these two drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/20\">",
"     20",
"    </a>",
"    ]. If the organism does not produce beta-lactamase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    is also an effective therapy.",
"   </p>",
"   <p>",
"    We recommend a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g IV every four to six hours) in adults; therapy should be continued for at least seven days.",
"   </p>",
"   <p>",
"    Pharyngeal colonization persists after curative therapy and may require a short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    if there are children in the household at risk for invasive Haemophilus infection. This is a rare situation because conjugate vaccines for H. influenzae type b are widely used and highly effective. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Chemoprophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Listeria monocytogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria, a gram-positive bacillus, is an important cause of bacteremia and meningitis, particularly in elderly adults (in whom it accounts for approximately 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/6\">",
"     6",
"    </a>",
"    ]), pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/21\">",
"     21",
"    </a>",
"    ], and patients with impaired cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/22\">",
"     22",
"    </a>",
"    ]. When Listeria invades the bloodstream, it has a tropism for the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/23\">",
"     23",
"    </a>",
"    ]. It is more likely than other causes of meningitis to cause small brain abscesses, especially in the midbrain and brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/24\">",
"     24",
"    </a>",
"    ]. These lesions can account for many of the long-term sequelae of listerial meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Drugs of choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria has traditionally been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (2 g every four hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (4 million units every four hours), since resistance to these drugs is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/25\">",
"     25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    is added for synergy, despite its poor penetration into the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/26\">",
"     26",
"    </a>",
"    ]. The gentamicin dose (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in a person with normal renal function) is divided into three equal doses. Gentamicin has not been studied as a synergistic drug with any therapy other than the penicillins.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     Ampicillin",
"    </a>",
"    is given for at least 21 days in patients with Listeria meningitis;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    is given until the patient improves (for at least the first week) or, in poor responders, for up to three weeks if there are no signs of nephrotoxicity or ototoxicity. Patients with cerebritis or rhombencephalitis should be treated for at least six weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a penicillin- or cephalosporin-allergic patient cannot be desensitized and receive a beta-lactam antibiotic, an alternative therapy is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [based on the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component] IV every 6 to 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5,27\">",
"     5,27",
"    </a>",
"    ]. In one retrospective series, therapy with trimethoprim-sulfamethoxazole plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    correlated with a lower failure rate and fewer neurologic sequelae than ampicillin combined with an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/28\">",
"     28",
"    </a>",
"    ], although the results of this small study are not compelling enough to make a change in recommended therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imipenem and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    have excellent in vitro activity against Listeria. Meropenem has been used to successfully treat some patients with Listeria meningitis, although more data are needed. Some newer fluoroquinolones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    show good in vitro activity against Listeria, but clinical experience is mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Alternative drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gram-negative bacilli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerobic gram-negative bacilli such as Escherichia coli and Klebsiella species are rare causes of community-acquired meningitis in adults, but are a common cause of healthcare-associated infections, mostly following neurosurgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/29\">",
"     29",
"    </a>",
"    ]. In a review of 493 episodes of bacterial meningitis in the Boston area from 1962 to 1988, gram-negative bacilli accounted for 3 percent of community-acquired cases and 33 percent of nosocomial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the availability of third-generation cephalosporins, it was often necessary to instill an aminoglycoside such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    directly into the cerebrospinal fluid. It is now possible to cure these infections with high doses of systemic cephalosporins. However, given the emergence of strains of gram-negative bacilli that are resistant to the third-generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/30\">",
"     30",
"    </a>",
"    ], use of other agents (given intravenously, with or without intraventricular therapy) may need to be considered. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Resistant gram-negative bacilli'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the difficulty in curing meningitis caused by gram-negative bacilli, a repeat CSF sample should be considered for culture two to three days into therapy to help assess the efficacy of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Repeat CSF analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of therapy should be at least 21 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Resistant gram-negative bacilli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organisms such as Pseudomonas aeruginosa and Acinetobacter spp are often resistant to many commonly used antibiotics.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    (2 g IV every eight hours) has been the most consistently effective cephalosporin for P. aeruginosa infections, including meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     Cefepime",
"    </a>",
"    , which has a similar gram-negative spectrum as ceftazidime, has also shown efficacy in isolated case reports, although it is not approved for the therapy of meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/32\">",
"     32",
"    </a>",
"    ]. Either agent can be given with an aminoglycoside, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day divided into three doses).",
"   </p>",
"   <p>",
"    Carbapenems such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    may be used in patients with meningitis caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    -resistant strains of various gram-negative bacilli, such as Acinetobacter spp. Meropenem is an effective drug in the treatment of meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/33\">",
"     33",
"    </a>",
"    ], and it has a lower epileptogenic potential then imipenem [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/34\">",
"     34",
"    </a>",
"    ]. Imipenem should be used with caution since it has been associated with seizures when doses exceeding 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    are given to patients with impaired renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of gram-negative meningitis caused by isolates that are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , and the carbapenems is challenging due to the toxicity of alternative agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited data on their use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/29\">",
"     29",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    (usually formulated as colistimethate sodium) is an alternative agent for Acinetobacter meningitis, but its use is limited by the potential for severe nephrotoxicity. In difficult to eradicate infections, colistin can also be administered by the intraventricular or intrathecal route [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) have been used in some patients with gram-negative meningitis, but there are only limited data about their efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/15,39\">",
"     15,39",
"    </a>",
"    ]. Options for the treatment of meningitis caused by resistant gram-negative bacilli are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=see_link\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link\">",
"     \"Treatment and prevention of Acinetobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual duration of therapy is 21 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108515050\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus meningitis is typically associated with penetrating head trauma or neurosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"     5",
"    </a>",
"    ]. Given substantial rates of methicillin-resistant Staphylococcus aureus (MRSA),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 to 12 hours if renal function is normal) should be used as initial therapy when S. aureus is suspected or proven (",
"    <a class=\"graphic graphic_table graphicRef71968 \" href=\"UTD.htm?12/37/12893\">",
"     table 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60707 \" href=\"UTD.htm?17/45/18141\">",
"     table 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    If susceptibility testing reveals methicillin-sensitive S. aureus, therapy should be changed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four hours) or&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g IV every four hours). If the organism is methicillin-resistant, vancomycin should be continued and dosed to achieve serum trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant drawback to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is its poor penetration into the cerebrospinal fluid (CSF) of approximately 1 and 5 percent with uninflamed and inflamed meninges, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    can be added to vancomycin at a dose of 600 mg orally once daily or 300 to 450 mg twice daily because it achieves bactericidal concentrations in the cerebrospinal fluid regardless of meningeal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5,40,44\">",
"     5,40,44",
"    </a>",
"    ], although there are few data to support this [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    has good CSF penetration of approximately 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/40,48-50\">",
"     40,48-50",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) has moderately good CSF penetration (13 to 53 percent for TMP and 17 to 63 percent for SMX) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/40,51,52\">",
"     40,51,52",
"    </a>",
"    ]. In a rabbit meningitis model, CSF",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    penetration was 5 to 6 percent, and achieved adequate concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/40,53,54\">",
"     40,53,54",
"    </a>",
"    ]. Based upon case reports and case series of patients with central nervous system (CNS) infections caused by MRSA, alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    include linezolid (600 mg IV or orally twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/55-58\">",
"     55-58",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    -sulfamethoxazole (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 to 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/40,51,59\">",
"     40,51,59",
"    </a>",
"    ] and daptomycin (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily) usually combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Although there are insufficient data regarding the efficacy of these regimens for the treatment of meningitis caused by MRSA, these agents are reasonable alternatives when vancomycin cannot be used or is ineffective. Further studies are needed to establish the benefit of these agents for the treatment of meningitis.",
"   </p>",
"   <p>",
"    The duration of therapy for S. aureus meningitis is 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     REGIMENS IN PATIENTS WITH DRUG ALLERGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to therapy in patients with antibiotic allergies is challenging given the importance of early initiation of therapy and the role of beta-lactam antibiotic regimens in the therapy of bacterial meningitis. Although it is optimal to desensitize patients with a history of anaphylaxis to beta-lactams who require therapy with this antibiotic class, an alternative regimen must be used while the desensitization is being performed. Furthermore, the decision of whether a beta-lactam is a necessary part of the regimen is based on the Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture data, the latter of which can take several days to yield an organism.",
"   </p>",
"   <p>",
"    For some bacteria, regimens that do not include a beta-lactam are sufficient but for others a beta-lactam is the optimal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H22#H22\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Beta-lactam allergy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Alternative agents'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Listeria monocytogenes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTPATIENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient antibiotic therapy may be appropriate for selected patients with bacterial meningitis because when complications occur, they usually happen within the first two to three days of therapy. Treatment outside of the hospital leads to decreased costs of hospitalization, decreased risk of development of nosocomial infections, and improved quality of life. Patients who are candidates for outpatient therapy should continue to receive intravenous antibiotics for the entire course. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Route of administration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following criteria have been suggested as a guide for outpatient antibiotic therapy in patients with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/5,62,63\">",
"     5,62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inpatient therapy for &gt;6 days",
"     </li>",
"     <li>",
"      Absence of fever for at least 24 to 48 hours prior to initiation of outpatient therapy",
"     </li>",
"     <li>",
"      No significant neurologic dysfunction, focal findings, or seizure activity",
"     </li>",
"     <li>",
"      Clinical stability or improving infection",
"     </li>",
"     <li>",
"      Ability to take fluids by mouth",
"     </li>",
"     <li>",
"      Access to home health nursing for antibiotic administration",
"     </li>",
"     <li>",
"      Reliable intravenous line and infusion device (if needed)",
"     </li>",
"     <li>",
"      Daily availability of a physician",
"     </li>",
"     <li>",
"      Established plan for physician visits, nurse visits, laboratory monitoring, and emergencies",
"     </li>",
"     <li>",
"      Patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family compliance",
"     </li>",
"     <li>",
"      Safe environment with access to a telephone, utilities, food, and refrigerator",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some forms of bacterial meningitis can be prevented by successful vaccination and temporary protection can be provided in certain cases with chemoprophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the major causes of bacterial meningitis in adults, vaccines are available for S. pneumoniae, N. meningitidis, and H. influenzae. Vaccines against S. pneumoniae and N. meningitidis are recommended for adults with a variety of risk factors for infection. Routine immunization of adults against H. influenzae type b is not recommended, except for those with prior splenectomy. The indications for vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Haemophilus influenzae vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Specific organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a role for post-exposure chemoprophylaxis to prevent spread of meningococcal and Haemophilus meningitis under certain circumstances, but not for pneumococcal disease. Indications for chemoprophylaxis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Antibiotic prophylaxis of close contacts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Basilar skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basilar skull fractures with underlying dural tears are associated with CSF leaks and predispose patients to meningitis because of the potential for direct communication of bacteria in the upper respiratory tract with the central nervous system. Antibiotics are sometimes given prophylactically, but their role for preventing bacterial meningitis has not been established. A meta-analysis evaluated 22 randomized or nonrandomized controlled trials of prophylactic antibiotics for preventing meningitis in patients with a basilar skull fracture and were not able to document improved outcome with antibiotics whether there was evidence of CSF leakage or not [",
"    <a class=\"abstract\" href=\"UTD.htm?14/60/15306/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       Patient information: Bacterial meningitis (The Basics)",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among adults with bacterial meningitis in the United States, Streptococcus pneumoniae and Neisseria meningitidis are the most common infecting organisms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic selection must be empiric immediately after CSF is obtained or when lumbar puncture is delayed. In such patients, antibiotic therapy needs to be directed at the most likely bacteria based upon patient age and underlying comorbid disease (",
"      <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that antibiotic therapy be initiated immediately after the performance of the lumbar puncture (LP) or, if a computed tomography scan of the head is to be performed before LP, immediately after blood cultures are obtained (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      should be given shortly before or at the same time as the first dose of antibiotics, when indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H16#H16\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Empiric therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For adults in the developed world with suspected bacterial meningitis in whom the organism is unknown or Streptococcus pneumoniae is confirmed, we suggest administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Dexamethasone should be continued if the CSF Gram stain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the CSF or blood cultures reveal S. pneumoniae. The indications for dexamethasone in patients in the developing world with suspected or confirmed bacterial meningitis are less certain and are discussed in detail elsewhere.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      is added to the regimen in patients receiving dexamethasone under certain circumstances. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"       \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rather than empiric therapy, antibiotics should be directed at the presumed pathogen if the Gram stain is diagnostic (",
"      <a class=\"graphic graphic_table graphicRef75922 graphicRef60707 \" href=\"UTD.htm?5/11/5310\">",
"       table 1B-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Regimens based upon Gram stain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antibiotic regimen should be modified further, when indicated, based on the CSF culture and susceptibility results (",
"      <a class=\"graphic graphic_table graphicRef81209 graphicRef60707 \" href=\"UTD.htm?7/17/7455\">",
"       table 1B, 1D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Therapy for specific pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the general limitation in antibiotic penetration into the CSF, all patients should be treated with intravenous antibiotics. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Route of administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pathogen-directed therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the initial therapy of S. pneumoniae, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      <strong>",
"       plus either",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      rather than a third-generation cephalosporin alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The dosing for patients with normal renal function is:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      &mdash; 2 g IV every 12 hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      &mdash; 2 g IV every four to six hours",
"      <br/>",
"      <br/>",
"      If the isolate is susceptible to third-generation cephalosporins (minimal inhibitory concentration [MIC] &lt;1.0",
"      <span class=\"nowrap\">",
"       mcg/mL),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      should be discontinued (",
"      <a class=\"graphic graphic_table graphicRef81209 graphicRef60707 \" href=\"UTD.htm?7/17/7455\">",
"       table 1B, 1D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'First-line regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the initial therapy of N. meningitidis, we recommend a third-generation cephalosporin, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , rather than penicillin, while awaiting susceptibility data (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef75922 graphicRef60707 \" href=\"UTD.htm?5/11/5310\">",
"       table 1B-C",
"      </a>",
"      ). If the isolate is susceptible to penicillin, either a third-generation cephalosporin or penicillin may be used to complete the course of therapy (",
"      <a class=\"graphic graphic_table graphicRef81209 graphicRef60707 \" href=\"UTD.htm?7/17/7455\">",
"       table 1B, 1D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neisseria meningitidis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred regimens for other causes of bacterial meningitis are discussed above (",
"      <a class=\"graphic graphic_table graphicRef75922 graphicRef60707 \" href=\"UTD.htm?5/11/5310\">",
"       table 1B-C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81209 graphicRef60707 \" href=\"UTD.htm?7/17/7455\">",
"       table 1B, 1D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Haemophilus influenzae'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Listeria monocytogenes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Gram-negative bacilli'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108515050\">",
"       'Staphylococcus aureus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal regimens for patients with severe drug allergies depends upon the organism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H22#H22\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Beta-lactam allergy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Alternative agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Listeria monocytogenes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccines against N. meningitidis and S. pneumoniae are recommended for adults at increased risk of these infections. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a role for post-exposure chemoprophylaxis to prevent spread of meningococcal and Haemophilus meningitis under certain circumstances. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/1\">",
"      de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/2\">",
"      Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/3\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/4\">",
"      Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA 1999; 282:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/5\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/6\">",
"      Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/7\">",
"      Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/9\">",
"      Par&iacute;s MM, Ramilo O, McCracken GH Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/10\">",
"      John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/11\">",
"      Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994; 38:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/12\">",
"      Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007; 44:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/13\">",
"      Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/14\">",
"      Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/15\">",
"      Cottagnoud P, T&auml;uber MG. Fluoroquinolones in the Treatment of Meningitis. Curr Infect Dis Rep 2003; 5:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/16\">",
"      Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother 2008; 61:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/17\">",
"      S&aacute;ez-Llorens X, McCoig C, Feris JM, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     Siegel JD, Rhinehart E, Jackson M, et al. Healthcare Infection Control Practices Advisory Committee 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, June 2007. file://www.cdc.gov/ncidod/dhqp/gl_isolation.html (Accessed February 4, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/19\">",
"      Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/20\">",
"      Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/21\">",
"      Mylonakis E, Paliou M, Hohmann EL, et al. Listeriosis during pregnancy: a case series and review of 222 cases. Medicine (Baltimore) 2002; 81:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/22\">",
"      Skogberg K, Syrj&auml;nen J, Jahkola M, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis 1992; 14:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/23\">",
"      B&uuml;la CJ, Bille J, Glauser MP. An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis 1995; 20:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/24\">",
"      Dee RR, Lorber B. Brain abscess due to Listeria monocytogenes: case report and literature review. Rev Infect Dis 1986; 8:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/25\">",
"      Clauss HE, Lorber B. Central nervous system infection with Listeria monocytogenes. Curr Infect Dis Rep 2008; 10:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/26\">",
"      Cherubin CE, Appleman MD, Heseltine PN, et al. Epidemiological spectrum and current treatment of listeriosis. Rev Infect Dis 1991; 13:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/27\">",
"      Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis 1986; 8:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/28\">",
"      Merle-Melet M, Dossou-Gbete L, Maurer P, et al. Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature. J Infect 1996; 33:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/29\">",
"      van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/30\">",
"      O'Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation cephalosporin resistance among Gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. J Antimicrob Chemother 2006; 57:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/31\">",
"      Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/32\">",
"      Rousseau JM, Soulli&eacute; B, Villevielle T, Koeck JL. Efficiency of cefepime in postoperative meningitis attributable to Enterobacter aerogenes. J Trauma 2001; 50:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/33\">",
"      Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/34\">",
"      Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000; 22:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/35\">",
"      Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/36\">",
"      Rodr&iacute;guez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 2008; 61:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/37\">",
"      Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007; 29:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/38\">",
"      Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005; 43:4916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/39\">",
"      Reddy, P, Das, S, Chandler, JP, Noskin, GA. Stenotrophomonas maltophilia meningitis treated with moxifloxacin: a case report and review of the literature. Infect Dis Clin Practice 2006; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/40\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/41\">",
"      Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/42\">",
"      Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007; 43:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/43\">",
"      Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol 2008; 69:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/44\">",
"      Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/45\">",
"      Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/46\">",
"      von Specht M, Gardella N, Tagliaferri P, et al. Methicillin-resistant Staphylococcus aureus in community-acquired meningitis. Eur J Clin Microbiol Infect Dis 2006; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/47\">",
"      Pintado V, Meseguer MA, Fort&uacute;n J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/48\">",
"      Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/49\">",
"      Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007; 51:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/50\">",
"      Nagashima G, Okamoto N, Okuda M, et al. Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother 2008; 14:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/51\">",
"      Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/52\">",
"      Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984; 26:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/53\">",
"      Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006; 57:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/54\">",
"      Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/55\">",
"      Gallagher RM, Pizer B, Ellison JA, Riordan FA. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008; 57:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/56\">",
"      Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007; 35:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/57\">",
"      Naesens R, Ronsyn M, Druw&eacute; P, et al. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 2009; 58:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/58\">",
"      Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/59\">",
"      Vartzelis G, Theodoridou M, Daikos GL, et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005; 33:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/60\">",
"      Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/61\">",
"      Wallace MR, Sander AW, Licitra C, et al. Methicillin-resistant Staphylococcus aureus meningitis successfully treated with daptomycin. Infect Dis Clin Pract 2009; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/62\">",
"      Waler JA, Rathore MH. Outpatient management of pediatric bacterial meningitis. Pediatr Infect Dis J 1995; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/63\">",
"      Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/60/15306/abstract/64\">",
"      Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2006; :CD004884.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1283 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15306=[""].join("\n");
var outline_f14_60_15306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Regimens based upon Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Route of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adjunctive dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THERAPY FOR SPECIFIC PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - First-line regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Listeria monocytogenes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Drugs of choice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gram-negative bacilli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Resistant gram-negative bacilli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108515050\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      REGIMENS IN PATIENTS WITH DRUG ALLERGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTPATIENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Specific organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Basilar skull fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pathogen-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1283|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/37/12893\" title=\"table 1A\">",
"      Empiric abx purulent mening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/45/18141\" title=\"table 1B\">",
"      Bacterial meningitis adult antibiotic dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/57/11164\" title=\"table 1C\">",
"      Abx for meningitis based on Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/55/12158\" title=\"table 1D\">",
"      Meningitis treatment based on susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/13/16605\" title=\"table 2\">",
"      Susceptibility of pneumococci",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38549?source=related_link\">",
"      Pathogenesis and pathophysiology of bacterial meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_60_15307="Endocrine disorders associated with childhood obesity";
var content_f14_60_15307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected endocrine disorders associated with childhood obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Cortisol excess (corticosteroid medication, Cushing syndrome)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth hormone deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudohypoparathyroidism&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         ROHHADNET syndrome",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired hypothalamic lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        After surgery for craniopharyngioma&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diencephalic&nbsp;tumor&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Congenital or acquired hypoventilation syndromes&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ROHHADNET: rapid onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation, neural crest tumors.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15307=[""].join("\n");
var outline_f14_60_15307=null;
var title_f14_60_15308="Exam in musculoskeletal CP";
var content_f14_60_15308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical examination in musculoskeletal chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart, lungs, abdomen (to rule out visceral source)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions (clue to psoriatic arthritis or SCCH syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocular exam (uvetis, conjunctivitis suggestive of spondyloarthropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Musculoskeletal examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thoracic spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Localized tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chest expansion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lumbar spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Forward flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sacroiliac tenderness to compression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tender points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest wall examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Observation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Localized swelling, particularly costochondral junctions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Palpation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acromioclavicular and sternoclavicular joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sternum and xiphoid costochondral junctions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Costovertebral joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Maneuvers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Crowing rooster maneuver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Horizontal arm flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hooking maneuver",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15308=[""].join("\n");
var outline_f14_60_15308=null;
var title_f14_60_15309="BOS after lung transplant";
var content_f14_60_15309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Freedom from bronchiolitis obliterans in adult lung recipients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 266px; background-image: url(data:image/gif;base64,R0lGODlh6gEKAdUAAP///4CAgAAzmQAAAMDAwEBAQMDN5tDQ0EBms4CZzBAQECAgIBBAn6Cz2TAwMPDz+XBwcODm87CwsGBgYCBNpqCgoFBzuVBQUJCQkPDw8LDA39DZ7JCm0zBZrHCNxmCAv+Dg4AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADqAQoBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8SwEcXIyYoEAc3OBEUMDB8aytbXfszOAQUBRBEMAuLT1djm53fNRgYeFOIC0w0P6PT1a+pIG+3vAhby9gADfsGnRF8Hfv7mCVzIUApBJhE4HHzXgcOxhhgzGnnoJOJEcRUvahy5kCOUCA0s8OuQYAPJl/VMSnmQkh8FDy5h6lQmkwpN/wvhxN00sLOosJ5XNHwICo+D0ae8kGZRGrQDUahYa0ndkiAoApFZw7bauuWBh3cfFIpdi4oslwgq4SVQy7ZuKLddDCAY18Cu3094vWhwJ4DC1b+ILwX+wsFrzsSQIy3+8iABWrCRMyeaDCbCh3dzNYs+xDnMhr1NR6sWVFqMAcIUyq2eraf1mAZeD9PePcf2mMpBLWDmTfyetzwPPovzQLd45AMBDgCAUEACG99mIqBmkMC5ZggLMmAYQB6aGuxnDExkgCCBhube1xaAAKDAgAoOJhgH1JhfYQsJ6BYfVt0AMIACAHCzXyAGNOABait9wMFjA+4EgQITDHABABMUsP9gIQZw8MFH7yDgQQPDVdgQCAqUl4ECx6WB3hwPGJCABYT51wECPHqQwI8aGCDkA/CpmAx00EAHwoeNRKBBAhD6JyU/JnIgoJHDaGMek5FEUKOQT/74II8k2gSgBhukiCUuGZI3gH5cguLkjTnyo+aatFQwgAPNOHBfnKWE+KA4FuC5SwEbDnGBh1VI0MySQjiKAaRIzGiJAeL0ZSguBQ6hIBUZOtAiNBDsqYAClG4UYyuWMXDnpq5MoIB1AEiAYRXkZRDAAAFkcCAA49FX6aqtHNQBrLaw6OaBqUaR4QIOOJABAQN4SC2jR1h6CTgCdIcsLQfYV610VYznpwIHXAv/gLpCaONMp7A0IM6V3ypzQLXAjrtnrRoO4W4z8MKiEgVF1qsKCNJxQywUIBwoQYb6LTCABBf8OewsD7hTqMGuNKyhmxhUUYHEGGYAwAHnCnvxLBtkyvFY1VZLgAPYoqGtJq1S+PIpChb4qYwLw7LXsTunEoACBSiwQAFLA/rKA+F4UHRby5JX8xk3b6KBOLJNPQoIBIQtNrlA43IWAwV7TU/WnByEgNoMsb3JBuF4CzdAcm8irwA6331O3pvEVSW9flcinjMVOD1LBFNScOarhS8isZtXmwH4JhFs8CSOUyIAYAMGpB05IRqOrbgugkbpn+cJgA756HpAAGcbl5sS/0GDN6pO5Yl9w56HnpSfXkyNDeQ+ZQcShu47HgcW4LzKNgdNz5wI1CnUmcovD8cC0mPdPUA1JjCilAwQrv0Z4CEuPEMNDiqOU+ezIa7V62f0QFwWiB4/GOmaft73L+GAUHq3vzEQgGz/E8sG3MEAAhbQCwdo0Z5MlkCxPOAg5XsgGRbAvQvNLnpsuaDLNBiGAZjnZyAMoXI0RUIvLOACBJBAfuq3E+VIrYVdAN6BEOi9v5xFAB/AYRegM6nrABAqe0uLELMAAejR0Ch764D+lsiEDr2hdugwQDikSMVywagZiatgYuhWGBZ2EQrzw5cYx0gYBJjvjEUgQAb6FzYeWv/uiBbsijg+8LozmhACYaQdHtfimXGEBo5I0NDS1LdGzeiFIiZyT/bgWKqqVa4MWGTI3qYkgB35KEh9hB3KJuC/stHmARswwJMeVKbVuSeUiJzCvxSmohqtEgGtZM8rY7mFWQYMT9RjyjjaowFY8pIJmbRLMKU0uGNWIZmJoV7jsDdFFR0OjE9E1pw4J6U3Gmly9Gvk6FLHl3qVro7Z9Nr99vgt2V1xkH6zTCeNuRsdqtGUGtQiPLzpnOY9L513i8BE7IYl7r1zicrJ35rSh01xahA3ZcRSGi9JBmhiaYFCMaN36HhAgI6OJrDRqHM6asRYNiCkG5WgtDyqvZOW6AP/7nEgZDgYAA+y9Hyb1FF7QKcZEwoBhT10phCExIEHCfMd7PGAlehJkhfGcIYOFepQi4dLTiIApmgKiw7RdVM4ak58ugPJTvnJECI2K6hSlcLtioqAow5TqULCiNjmakdMwjOtS8BdVafkAaYOo2rhxCdeufDVD0SpA/+wRzMWMIHFOvGOgyWDUvhBDYD4NEGJEmxkw0CTj1AAfuhQgAOeStExWDSyEdhHRM9hT1ppdrNlcOlqsQGd6JQUtmqQLQVEWgxHgcC2UcUtGXTL22BUkgAX+CBahZtbwjDAAhMiBoZGC1TIMrcN/UEqdGVqCxMWgABWDO51zRAioPDjudE9/5QDXjiAkIl3vGjYAAfMq9302iKC5Fnpe+GrBvnSdxzbtQVJu8pfMfhXmEltAHdJgTITLsC9ry1wHQ7MzOSpQlQKIAB1rgA2sknqrEQ4rYSr8NXqSakDAJpkKCb23epCIQN+YlSpMAzin951xHIInwVaSQFiLngSCsBAdRhrhUp6yFcICpa/tkFLHBsiRIYlHzGr2YhduWlLUqDWrqyFL3ati8m/dLIhNuCgtvrHcVa6hJAv4FopZGABEFCXnO+pKjE/gsweaGUHeBeJCgSyCtRaVgHu5QB+ZbbOdpZEea0nDh5d9UcBEpJf47AoLEyLAOaSjsQoZrFs3TjRhXjAk//CyslG8wimPxKSASYthpGVkgrsarACHhviT4MaERG4nZAgbVgelfrXwC61FyZK4Ft3SdW8dnSwl+2FCmzjz8s19lNMWAEsF1va6OBVfl4dbWzvJI2BTaG3jSKeRTY0wuOGyQFq3O10G0zE7mYLvOMtlnnTuxaAFAIGbI0Fe987FtPaNnJLKwZ///sVgV6Wcq17cI381twYoCC6G76QdR+U4iOpgATp3G6MC6RFzpvPtT0ejFlfnOQNcacbDI7yVBB7vy3HBnVCTuuK8jvmmWE5zkvRYAI8eOQ71wWGNUzwMOg86KJgMTOKDoajIx0UQR7ywu36dMUuy9oMrzo61tz/ZnFr3RyOAsBv62rzr6PDoPU5dMfNXozLurjsbMcGYzMA46nDPe7WsHJ5gI53WFQAUV1fe9+B0cQ0+PLmg59FeM9w+MQnAwNfDAC0s+54Ybx84pXnBUfJblrEZ/4VvgUu5j+fi+Mml++kN8V0l4761JPCu+Bl+kA873qXr7diEPZ67XeB3wm2fveiGDDMgQ96RGFd98Svxb3cxO67J98WR5OArWj/TOo/HzCMCrPgrw8zS/6e+4oBrOy94HTwa8X65v8b+tOPjfKzPxbuf/8r4i//say//sigP/5Vof/9t+X+/ncUABiAwNB/BEgKBniAopCACggKDNiAnvCAEMgJ/xI4gZpQgRaICRiYgYaQAc5WARK3Mhw4DDG2L0qwgSMoCBLQLxUTeLWWgkfBKwkig0u2Dc7DZDiYgzq4gzzYgz74g0AYhEI4hERYhEZ4hEiYhEq4hEzYhE7Yg8eHB7viDVNIBL7UDU+ogzeYhVqIhVzYhV8IZl4Yhu8yhmTIDWZIhlt4hgCThl+4hmyofXigZKWSe4jmfJ03eloATXw4gCKIh0bnh572Bw2zAD43AM2XTH2oh1mwiJRXcIJ4h3n4iHowMgOwAJNXBIoYiZrIiZIYiNvHBY5IdaRYilXmiTYWil2QSaMIiKBIibOnioOwibK4BayIiqkIi7Goi6uIi/8J4ouGF4VeEDaMJ4xgQIxkgIxloIzJaIxdwIwG5Iy9JI3TCIPWeI3YmI3cV1ucRwiOEgDUKAiX9gi1FY5/UI6LMGAeKHkhWAgryEETk47L4oKH0CaO8CxySAh6Ao/AyD9bNgQlWGiI4CcHQGiLADb5Mn5/sILk0Qh6onaKYB8S4GWFIC6MsoIb0oKI0JAGMgCOoCd2RwgvYmWNUDH2kWGMoCdIw1WIwC5VWIWHwJEcuQhvhiqMcAGFNpMR2V7jsQCMQACiRR6ZKAguKYMwaQgtQne/sggHsAAsuQiAdZM+pZOI0CInQ5WEwC502F6IkCHN8Cbp2CKN1Y/RGGjm2Af/DzkeCtkHEoMBPYkIB2AuclSIh9h8fpABFaMh7WgIeoeVieCXh3Ah1bKXhtBgGtKNfpBG0GCJmKiNjvmYkBmZkjmZlFmZlnmZmJmZmrmZnNmZnilEYQMp6WKXn8l/+PIiCkCYpdkKbzYxuxIyugJ4QjBzEyAdzHAA1QYsz0OaqwkJ72iCohIABAkAHaQ0M9giAZAhECCcZ9mbjCAu0nEv3eCV60IdVrkrtFIxFwCOzskJ7HItz4CRMuSRu2IeGTABfhKP3ZkJXnYq1YYBzsYrEiAxM2geE4ABGsaV64kJXnYAebkAEgBjl0if5flTLWJy+5mgCrqgDNqgDvqgEBqhCRI6oRRaoWYXBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data on the development of bronchiolitis obliterans syndrome (BOS)&nbsp;from patients undergoing transplantation between April 1994 and June 2004.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Based on data from the Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Lung and Heart-Lung Transplant Report - 2005. Adapted from: Trulock, et al. Journal of Heart and Lung Transplantation 2005; 24:956.",
"     <br>",
"      2. For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled \"Freedom from Bronchiolitis Obliterans Syndrome\"&nbsp;&nbsp;at:",
"      <a href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\" style=\"FONT-STYLE: italic\">",
"       file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15309=[""].join("\n");
var outline_f14_60_15309=null;
var title_f14_60_15310="RR of CV lisin vs chlor ALLHAT";
var content_f14_60_15310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Combined cardiovascular disease outcomes with lisinopril vs chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of CV outcomes with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of combined cardiovascular disease outcomes in all patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of these outcomes in total and in most subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15310=[""].join("\n");
var outline_f14_60_15310=null;
var title_f14_60_15311="Steroid dependent UC";
var content_f14_60_15311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Steroid-dependent ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 542px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     6-MP: 6-mercaptopurine; AZA: azathioprine; anti-TNF: anti-tumor necrosis factor agents.",
"     <br/>",
"     * Infliximab or other approved anti-TNF therapy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_60_15311=[""].join("\n");
var outline_f14_60_15311=null;
